Association of β 2-adrenergic agonists and tiotropium: is the combination justified?

array:20 ["pii" => "13084073" "issn" => "03002896" "doi" => "10.1016/S0210-5705(09)71003-9" "estado" => "S300" "fechaPublicacion" => "2005-05-15" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2005;41 Supl 2:24-31" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7222 "formatos" => array:3 [ "EPUB" => 101 "HTML" => 6417 "PDF" => 704 ] ] "itemSiguiente" => array:16 [ "pii" => "13084074" "issn" => "03002896" "doi" => "10.1016/S0210-5705(09)71003-9" "estado" => "S300" "fechaPublicacion" => "2005-05-15" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2005;41 Supl 2:32-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 10408 "formatos" => array:3 [ "EPUB" => 76 "HTML" => 9774 "PDF" => 558 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Controversias farmacológicas reflejadas en las guías y normativas nacionales e internacionales" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "32" "paginaFinal" => "37" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Pharmacological controversies reflected in national and international guidelines and recommendations" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P de Lucas Ramos, JM Rodríguez González-Moro, S López Martín" "autores" => array:3 [ 0 => array:2 [ "Iniciales" => "P" "apellidos" => "de Lucas Ramos" ] 1 => array:2 [ "Iniciales" => "JM" "apellidos" => "Rodríguez González-Moro" ] 2 => array:2 [ "Iniciales" => "S" "apellidos" => "López Martín" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13084074?idApp=UINPBA00003Z" "url" => "/03002896/00000041000000S2/v0_201307091044/13084074/v0_201307091046/es/main.assets" ] "itemAnterior" => array:16 [ "pii" => "13084072" "issn" => "03002896" "doi" => "10.1016/S0210-5705(09)71003-9" "estado" => "S300" "fechaPublicacion" => "2005-05-15" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2005;41 Supl 2:21-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6905 "formatos" => array:3 [ "EPUB" => 107 "HTML" => 6257 "PDF" => 541 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Corticoides inhalados: ¿a quién y cuándo?" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "21" "paginaFinal" => "23" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Inhaled corticosteroids: which patients and when?" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P Casan Clarà" "autores" => array:1 [ 0 => array:2 [ "Iniciales" => "P" "apellidos" => "Casan Clarà" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13084072?idApp=UINPBA00003Z" "url" => "/03002896/00000041000000S2/v0_201307091044/13084072/v0_201307091045/es/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Association of β 2-adrenergic agonists and tiotropium: is the combination justified?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "24" "paginaFinal" => "31" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "M Cazzola, MG Matera, KM O'Donnell" "autores" => array:3 [ 0 => array:3 [ "Iniciales" => "M" "apellidos" => "Cazzola" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "affa" ] ] ] 1 => array:3 [ "Iniciales" => "MG" "apellidos" => "Matera" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 2 => array:3 [ "Iniciales" => "KM" "apellidos" => "O'Donnell" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "affc" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Unit of Pneumology and Allergology. Department of Respiratory Medicine. A. Cardarelli Hospital. Naples." "etiqueta" => "a" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Unit of Pharmacology. Department of Experimental Medicine. Second University. Naples. Italy." "etiqueta" => "b" "identificador" => "affb" ] 2 => array:3 [ "entidad" => "Unit of Respiratory Medicine. Department of Internal Medicine. University of Rome Tor Vergata. Rome. Italy." "etiqueta" => "c" "identificador" => "affc" ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Association of β 2-adrenergic agonists and tiotropium: is the combination justified?" ] ] "textoCompleto" => " Introduction Current treatment for chronic obstructive pulmonary disease (COPD) is aimed at increasing airflow, decreasing respiratory symptoms (particularly dyspnea), decreasing exacerbations, and improving the quality of life. Consequently, it not surprising that both the Global Initiative for Obstructive Lung Disease (GOLD) guidelines1, and the recent American Thoracic Society (ATS)/European Respiratory Society (ERS) position paper for the diagnosis and treatment of patients with COPD2 emphasize the role of bronchodilators in symptomatic management of all stages of COPD. There are two primary pharmacologic classes of inhaled bronchodilators with different mechanisms of action which are used in the treatment of COPD: β2-adrenoceptor (β2-AR) agonists and quarternary ammonium anticholinergic agents3, which can be either short-acting (e.g., salbutamol, terbutaline, ipratropium or oxitropium) or long-acting (e.g., formoterol, salmeterol, or tiotropium). Both the GOLD Update and the ATS/ERS position paper recommend, for moderate-to-very severe COPD, use of regular treatment with long-acting bronchodilators rather than short acting bronchodilators, with the choice depending on the availability of medication and the patient's response1,2.For patients whose conditions are not sufficiently controlled by monotherapy, these guidelines highlight that combining medications of different classes, in particular an inhaled anticholinergic with a β2-AR agonist, seems a convenient way of delivering treatment and obtaining better results1,2. This includes better lung function and improved symptoms.Rationale for combining β2-adrenoceptor agonists and anticholinergic agents Postganglionic, parasympathetic-cholinergic nerves innervate the airways. When activated, these nerves are capable of obliterating the lumen of small bronchi and bronchioles, and markedly increasing airway resistance in larger, cartilaginous airways, by secretion of the bronchoconstricting mediator acetylcholine (ACh), which causes activation of muscarinic receptors at the level of the target cells, such as bronchial smooth muscle and goblet cells4. Conversely, sympathetic nerves may control tracheobronchial blood vessels, but no innervation of human airway smooth muscle has been demonstrated. β2-ARs, however, are abundantly expressed on human airway smooth muscle and activation of these receptors causes its relaxation5. Bronchodilatation may, therefore, be obtained either by stimulating the β2-ARs with β2-AR agonists, or by inhibiting the action of ACh at muscarinic receptors with anticholinergic agents. In any case, anticholinergics are more likely to decrease central airway resistance, although there are muscarinic receptors that are expressed in the smooth muscle of small airways which do not appear to be innervated by cholinergic nerves, and β2-AR agonists have a greater effect on peripheral airway resistance in patients with COPD6. It is reasonable to postulate that attempts to reduce bronchoconstriction through two distinct mechanisms (anticholinergic and sympathomimetic) with a different prevalent site of action may maximize bronchodilator response. Interestingly, the presence of small dense-cored vesicles containing adrenergic nerve varicosities, occasionally in close proximity to morphologically characteristic cholinergic nerve-endings, has been identified in human airways7, suggesting that catecholamines might modulate cholinergic neurotransmission (fig. 1). However, different studies have led to dissimilar conclusions. Early research papers based on force measurement alone suggested that stimulation of β2-ARs inhibits cholinergic neurotransmission8, most probably by the release of inhibitory prostaglandins from the airway mucosa9. However, interpretation of these data is seriously hampered by the large postjunctional effects of β2-AR agonists. Zhang et al10 were the first to report an excitatory β2-AR in airway parasympathetic nerves. After their report in studies on the horse, this receptor was subsequently reported in guinea pigs11 and in human airway parasympathetic nerves12. Activation of β2-ARs by isoproterenol, by the racemic mixture of specific β2-AR agonists such as salbutamol and formoterol or by R-enantiomers of β2-agonists can increase ACh release in a concentration-dependent manner13. Consistent with the results of β2-AR stimulation14, direct activation of the β2-AR-coupled Gs protein by cholera toxin, which increases the activity of adenylyl cyclase, caused an increase in ACh release in epithelium-denuded guinea pig trachealis11. In airway smooth muscle cells, however, stimulation of Gs protein directly opens large Ca2+-activated potassium (KCa) channels15, which has been found to decrease ACh release in guinea pig trachealis16. Recently, Brichetto et al17 have confirmed that β2-AR agonists attenuate cholinergic neurotransmission in the isolated bovine trachealis model and this happens by a mechanism not involving cAMP but KCa channels.<img src="6v41nSupl.2-13084073tab01.gif"></img>Fig. 1. Schematic presentation of the potential alternative role of β2-adrenoceptor (AR) in the pre-synaptic control of acetylcholine (ACh) release from airway parasympathetic nerve endings. A: circulating adrenaline; β2-AR: β2-adrenoceptor; M1 and M3: muscarinic M1 or M3 receptors; (>: neuronal activity; →: stimulatory effect; (=↓: inhibitory effect. Whatever the type of interaction between the two systems may be, combining β2-AR agonists and anticholinergic agents is pharmacologically useful. In fact, in the first case, the addition of a β2-AR agonist decreases the release of ACh because of the modulation of cholinergic neurotransmission by prejunctional β2-ARs and, consequently, amplifies the bronchial smooth muscle relaxation directly induced by the anticholinergic agent. On the contrary, in the second circumstance, the addition of an anticholinergic agent can reduce the peripheral bronchoconstrictor effects of ACh, whose release has been facilitated by the β2-AR agonist, and in this manner can amplify the bronchodilation elicited by the β2-AR agonist through the direct stimulation of smooth muscle β2-ARs.Combination therapy with ipratropium and a β2-agonistIt has been documented that standard doses of short acting β2-agonists do not give optimal results in patients with COPD and that an anticholinergic agent gives additional bronchodilation18. In addition, the reproducibility of responsiveness to bronchodilators in patients with COPD is improved when the pulmonary function test is performed using a combination of ipratropium and salbutamol18. In effect, although a few articles question the value of combination therapy with ipratropium bromide and a β2-AR agonist19,20, several large trials suggest that the two drugs, both at low doses21 and at high doses22,23, have complementary, or additive, bronchodilator actions without any increase in the incidence of adverse reactions, which makes them an excellent combination for the treatment of COPD. The inclusion of a second agent of a different class in a pharmacologic treatment regimen is associated with a lower rate of exacerbations in COPD24. The overall result is lower total treatment costs and improved cost-effectiveness.The introduction of long acting β2-AR agonist bronchodilators gives physicians additional therapeutic options for COPD. Both salmeterol and formoterol appear to be more effective than short acting β2-AR agonists25 and in patients with stable COPD they are more effective than anticholinergic agents26-28.Two published studies that had evaluated small cohorts suggested that there is no substantial additive effect when a long-acting β2-AR agonist is combined with ipratropium bromide given acutely at the clinically recommended dose (40 μg) in patients with COPD29,30, but it must be stressed that the dose of ipratropium bromide needed to produce near maximal bronchodilation is several times higher than the customary dosage31. In fact, the results of some studies suggest that higher than normal doses of an anticholinergic drug must be used for further relief of bronchospasm in patients with COPD when a single conventional inhaled dose of formoterol32 or salmeterol33 is given first.In any case, van Noord et al34 demonstrated that a 12-week treatment with salmeterol 50 μg twice daily plus ipratropium bromide 40 μg four times daily was more effective than salmeterol 50 μg twice daily in improving forced expiratory volume in 1 second (FEV1) and specific airway conductance. This study was the first to point out that the association of a long acting β2-AR agonist and an anticholinergic agent is useful in the long term therapy of stable COPD. Subsequently, D'Urzo et al35 not only confirmed this therapeutic possibility, but even documented that the addition of formoterol (12 μg twice daily) to ipratropium bromide (40 μg four times a day) is more effective than the addition of salbutamol (200 μg four times a day) in patients with COPD who required combined bronchodilator therapy. This finding clearly indicates that long-acting β2-AR agonists may represent the most effective option for combination therapy with an antimuscarinic agent.The functional impact of combining long-acting bronchodilators Clinical studies show that tiotropium administered 18 μg once daily improves lung function over its 24-h dosing interval, as shown by FEV1, forced vital capacity (FVC), peak expiratory flow rate (PEFR) and measures of hyperinflation and provides superior spirometric improvements compared with ipratropium 40 μg four times daily36. Considering this important finding, in an elegant review in which the pharmacological actions of the long-acting β2-AR agonists and a long-acting muscarinic antagonist (tiotropium bromide) were summarized, Tennant et al37 highlighted the need for investigating the combination of tiotropium bromide with a long-acting β2-AR agonist. Afterwards, Tashkin and Cooper38, using the traditional method of integrating research studies that, unfortunately, does not allow to determine if the differences between the study outcomes are due to chance, to inadequate study methods or to systematic differences in the characteristics of the studies, emphasized the advantage of tiotropium on long-acting β2-agonists, and suggested adding salmeterol or formoterol to tiotropium bromide, at least in patients suffering from COPD with more severe symptoms (stage III or IV of the GOLD classification1. However, Cazzola and Matera39 in an accompanying editorial comment highlighted that no published study has documented the superiority of tiotropium over formoterol, although two studies, specifically designed to explore the potential differences between tiotropium and salmeterol, seem to indicate a greater efficacy of tiotropium than long-acting β2-AR agonists40,41. The different pharmacodynamic profile of formoterol when compared to salmeterol25 might induce a different type of broncholytic effect, mainly if one considers onset of action or peak bronchodilation. This may lead to a different conclusion when comparing formoterol with salmeterol. Moreover, it is not known if the combination of a long-acting β2-AR agonist and a long-acting antimuscarinic agent provides further advantages in terms of bronchodilation over either drug alone, nor if the choice of the specific long-acting β2-agonist to be used is trivial.Acute functional effect of combining formoterol or salmeterol and tiotropium Some studies have tried to give an answer to these questions. A pilot investigational trial42, which enrolled 20 outpatients clinically diagnosed with stable COPD and a mean baseline FEV1 of 0.87 l (95% confidence interval [CI], 0.70-1.04) and FVC of 1.49 l (95% CI, 1.30-1.69), showed that 12 μg formoterol, either alone or in combination with 18 μg tiotropium, elicited a significantly faster onset of action (the change in FEV1 10 min after inhalation of formoterol alone [0.088 l; 95% CI, 0.049-0.127] was greater than that induced by tiotropium alone [0.039 l; 95% CI, 0.006-0.071], but not than that elicited by formoterol + tiotropium [0.085 l; 95% CI, 0.044-0.126]) (fig. 2 A). Moreover, this study also documented a trend for a greater maximum bronchodilation with combination than with formoterol or tiotropium alone (the mean maximum increases in FEV1 from pre-dosing value on each of the dosing days were 0.192 l [95% CI, 0.125-0.259] for formoterol, 0.176 l [95% CI, 0.100-0.253] for tiotropium, and 0.210 l (95% CI, 0.158-0.261] for the combination and occurred two hours after formoterol and three hours after inhalation of tiotropium and the combination, but the difference between treatments was not significant [p = 0.475]) (fig. 2 B). At twenty four hours, mean FEV1 continued to be significantly higher than pre-dosing value following tiotropium (0.084 l; 95% CI, 0.003-0.134; p = 0.003) and formoterol + tiotropium 0.088 l; 95% CI, 0.002-0.173; p = 0.045), but did not achieve significance for formoterol alone (0.058 l; 95% CI, 0.000-0.117; p = 0.051) (fig. 2 B). However, at this time point, the differences between treatments were not significant (p = 0.731). The failure to show a statistically significant difference between treatments when we explored the maximum bronchodilation and the duration of action was likely associated with an insufficient statistical power in the study. We believe that there was a possibility of a type II error, which supported the lack of significance that we have repeatedly observed. It is possible that a study with a larger sample would achieve statistical significance.<img src="6v41nSupl.2-13084073tab02.gif"></img>Fig. 2. Mean changes (± SE) in FEV1 (l) from pre-dosing value on each of the dosing days up to 90 min (A) and up to 24 h (B) after inhalation of formoterol 12 μg (FOR), tiotropium 18 μg (TIO), and tiotropium 18 μg + formoterol 12 μg (TIO + FOR). *p < 0.05; **p < 0.01; ***p < 0.001 versus baseline. (Data from Cazzola et al42.)The results of this study indicate that formoterol and tiotropium have different profiles (formoterol has a faster onset of action and greater bronchodilating effect, tiotropium has a longer duration of action, which allows for once daily administration) that make both agents attractive alternatives in the treatment of stable COPD. Moreover, the two drugs appear complementary: tiotropium ensures prolonged bronchodilation, whereas formoterol adds fast onset and a greater peak effect. However, because formoterol is given twice daily, but tiotropium is required only once daily, and results of our study do not allow suggesting the once daily dosing of formoterol, the challenge is to develop a combined inhaler that can be employed on a daily basis37. The pharmacodynamic characteristics of salmeterol might permit the once daily contemporaneous administration of the two drugs that could simplify the therapy39.In a further study43 that has enrolled 20 outpatients with stable COPD and a mean baseline FEV1 of 1.10 l (95% CI, 0.91-1.29) and FVC of 1.85 l (95% CI, 1.62-2.07), single doses of 18 μg tiotropium, 50 μg salmeterol, and 18 μg tiotropium + 50-μg salmeterol were given. The change in FEV1 30 min after inhalation of salmeterol alone (0.058 l; 95% CI, 0.032-0.083) was greater than that induced by tiotropium alone (0.037 l; 95% CI, 0.013-0.062), but not than that elicited by tiotropium + salmeterol (0.121 l; 95% CI, 0.073-0.170) (fig. 3 A). The difference between the improvement after salmeterol and that after tiotropium was not statistically significant (p = 0.231), but the differences between the improvement after tiotropium + salmeterol and that after tiotropium alone and salmeterol alone were statistically significant (p = 0.014 and p = 0.026, respectively). The mean maximum increases in FEV1 from pre-dosing value on each of the dosing days were 0.165 l (95% CI, 0.098-0.232) for tiotropium, 0.241 l (95% CI, 0.151-0.332) for salmeterol, and 0.290 l (95% CI, 0.228-0.353) for the combination and occurred four hours after inhalation of tiotropium or salmeterol and three hours after that of the combination (fig. 3 B). At twenty four hours, the mean FEV1 value was still higher than the mean pre-dosing value for tiotropium (0.042 l; 95% CI, 0.012 to 0.097; p = 0.119) and the tiotropium + salmeterol combination (0.051 l; 95% CI, 0.015-0.087; p = 0.008), but not for salmeterol alone (0.013 l; 95% CI, 0.041 to 0.014; p = 0.324) (fig. 3 B). At this time point, the differences between tiotropium and salmeterol and between salmeterol and tiotropium + salmeterol, but not that between tiotropium and tiotropium + salmeterol, were statistically significant (p = 0.010, p = 0.006, and p = 0.752, respectively).<img src="6v41nSupl.2-13084073tab03.gif"></img>Fig. 3. Mean changes (± SE) in FEV1 (l) from pre-dosing value on each of the dosing days up to 90 min (A) and up to 24 h (B) after inhalation of salmeterol 50 μg (SALM), tiotropium 18 μg (TIO), and salmeterol 50 μg + tiotropium 18 μg (SALM + TIO). *p < 0.05; **p < 0.01; ***p < 0.001 versus baseline. (Data from Cazzola et al43.) These findings support the possibility of combining tiotropium and salmeterol in patients suffering from stable COPD, but exclude the once-daily co-administration of the two drugs. The potential of salmeterol to increase its onset of action when combined with tiotropium is worthy of attention considering that both agents elicit a slow onset of action44,45. Ethier et al46 documented that at the lowest concentration of salmeterol needed to maximally stimulate cAMP accumulation, this long-acting β2-AR agonist antagonized muscarinic inhibition of cAMP accumulation and altered agonist binding to muscarinic receptors in bovine trachealis cells. Because salmeterol altered agonist, but not antagonist, binding and appeared to have an effect on the proportion of high affinity binding sites, Ethier et al46 speculated that salmeterol has a low affinity binding interaction with the muscarinic receptor/G-protein complex itself or reversibly alters the plasma membrane environment surrounding the complex. In any case, these effects of salmeterol did not depend on stimulation of β2-ARs. If this finding were also true for human airways, we could speculate that salmeterol reduces the bronchospastic activity of endogenous ACh, without influencing the effect of tiotropium. Salmeterol has also high affinity for muscarinic receptors47 and this indicates a potential for amplifying the action of tiotropium. However, the question of whether high local concentrations after inhalation of salmeterol could contribute to its therapeutic effects by antagonism with ACh on muscarinic receptors remains to be answered47.Functional effect of a regular treatment with formoterol or salmeterol and tiotropium Although these results indicate that a combination of tiotropium and a long-acting β-AR agonist is more effective than single drugs alone in inducing bronchodilation in patients suffering from COPD, there is a fundamental aspect of these studies, the evaluation of the impact of the three treatments only after acute administration, that must be taken into account. Acute administration is, in fact, a potential bias because it is well known that FEV1 steady state with tiotropium is reached within forty eight hours, while continued improvements in FVC can be expected over or beyond the first week of therapy48. The progressive increases in FVC beyond forty eight hours suggest that maintenance bronchodilator therapy is required to achieve maximal changes in hyperinflation. Data of a trial49 that compared the lung function response of the free combination of 18 μg tiotropium plus 12 μg formoterol once daily with 18 μg tiotropium once daily and 12 μg formoterol twice daily, with all treatments administered for 6-week periods, in 66 patients with moderate-to-severe stable COPD, documented that the free combination of once daily tiotropium plus formoterol was better than either of the single drugs for most of the spirometric endpoints. Tiotropium once daily was superior to formoterol twice daily during the daytime. However, during the night-time, tiotropium and formoterol provided similar bronchodilation. In particular, the average FEV1 area under the curve (AUC)0-24h was 85 ml after tiotropium, 62 ml after formoterol and 160 ml after tiotropium + formoterol, the average FEV1 AUC0-12h was 127 ml after tiotropium, 86 ml after formoterol and 234 ml after tiotropium + formoterol, whereas the average FEV1 AUC12-24h was 43 ml after tiotropium, 38 ml after formoterol and 86 ml after tiotropium + formoterol (fig. 4). All FEV1 AUC after tiotropium + formoterol were significantly (p < 0.05) larger than that of tiotropium or formoterol alone. The daytime, but not the night-time, use of rescue salbutamol was significantly reduced in patients receiving the combination of tiotropium + formoterol (p < 0.05 versus either drug alone). The documentation that tiotropium was more active than formoterol in daytime but not in night-time was, in our opinion, in agreement with the fact that the activity in the sympathetic system appears to be prominent during the day as reflected by the peak located around noon of the urinary catecholamine excretion, whereas the vagal system appears to be prominent during the remainder of the day50. In any case, these results indicate that once daily combination therapy of tiotropium + formoterol is safe and provides significant additive effects in patients with moderate-to-severe COPD. Moreover, they suggest that once daily administration of the two drugs could be a possibility in the treatment of stable COPD. A bronchodilator-mediated symptom benefit of the once daily combination is also reflected in significant decrease in salbutamol use as rescue therapy.<img src="6v41nSupl.2-13084073tab04.gif"></img>Fig. 4. Tiotropium 18 μg once daily (TIO qd), tiotropium 18 μg once daily + add-on formoterol 12 μg once daily (TIO + FORM qd) and tiotropium 18 μg once daily + add-on formoterol 12 μg twice daily (TIO + FORM bid) FEV1 AUCs calculated using the trapezoidal rule divided by the corresponding observation time to report in ml units. ap < 0.05 versus formoterol; bp < 0.05 versus tiotropium. (Data from van Noord et al49.) However, another trial that explored tiotropium maintenance therapy in 91 patients with COPD and the twenty four hour spirometric benefit of adding once or twice daily formoterol during two-week treatment periods51, documented that add-on therapy of a second formoterol dose significantly (p < 0.05) improved FEV1 and FVC variables when compared with tiotropium + formoterol once daily, although most of the spirometric add-on benefit was found with the morning formoterol dose. The average FEV1 AUC0-24h was 80 ml after tiotropium, 162 ml after tiotropium + formoterol once daily and 198 ml after tiotropium + formoterol twice daily, the average FEV1 AUC0-12h was 125 ml after tiotropium, 238 ml after tiotropium + formoterol once daily and 241 ml after tiotropium + formoterol twice daily, whereas the average FEV1 AUC12-24h was 37 ml after tiotropium, 89 ml after tiotropium + formoterol once daily and 156 ml after tiotropium + formoterol twice daily (fig. 5). FEV1 AUC12-24h of tiotropium + formoterol twice daily value was significantly (p < 0.05) different from that of tiotropium + formoterol once daily. Inspiratory capacity (IC), which is an index of hyperinflation, showed a circadian rhythm during both the baseline and the treatment periods. The improvements in IC with both tiotropium alone and when combined with formoterol paralleled those in FVC. Use of salbutamol as rescue therapy was comparable during add-on therapy of formoterol once daily and formoterol twice daily.<img src="6v41nSupl.2-13084073tab05.gif"></img>Fig. 5. Tiotropium 18 μg once daily (TIO qd), formoterol 12 μg twice daily (FORM bid) and tiotropium 18 μg + formoterol 12 μg once daily (TIO + FORM qd) FEV1 AUCs calculated using the trapezoidal rule divided by the corresponding observation time to report in ml units. ap < 0.05 versus formoterol; bp < 0.05 versus tiotropium. (Data from van Noord et al51.)The best strategy for adding long-acting β2-agonists and long-acting anticholinergics These findings raise an important question. What is the best strategy for adding long-acting β2-AR agonists and long-acting anticholinergics in COPD? Some studies have examined various strategies for adding short-acting β2-AR agonists and anticholinergics in COPD. Unfortunately, they have provided conflicting results. Rennard52 has correctly stressed that this may depend on the nature of the circumstances of the patient at the time when the study was carried out and may depend on the design by which the studies were conducted and the drugs administered.In one of our previous trials, which was the first to our knowledge that compared a long-acting β2-AR agonist and an anticholinergic agent given by sequential inhalation at the recommended dosages, we documented that the sequential administration of formoterol and oxitropium bromide induced an improvement in pulmonary function in a population of COPD patients similar to that examined in the present trial53. However, prior administration of the long-acting β2-AR agonist allowed a response to the anticholinergic drug, which was higher than that observed when inhalation of oxitropium was preceded by that of formoterol.In order to explore whether this finding is true even when tiotropium is used instead of oxitropium, we have examined the potential of an additive effect of a recommended dose of second long-acting bronchodilator (tiotropium or formoterol) in COPD patients under regular treatment with a long-acting bronchodilator of a different class (formoterol or tiotropium, respectively). We conducted a randomized, crossover trial in 20 patients with 18 μg tiotropium once daily and 12 μg formoterol twice daily over a five-day period for each drug, with a ten-day washout period54. At the end of each period, patients inhaled both drugs separated by 180 min in alternate sequence. Thirty minutes after inhalation of the last dose of tiotropium, there was a statistically significant increase of 0.099 l (95% CI, 0.062-0.138) in FEV1 over baseline (p < 0.0001) (fig. 6). The same was observed after inhalation of the last dose of formoterol (0.166 l; 95% CI, 0.064-0.168; p < 0.0002). The mean maximal change in FEV1 over baseline was 0.226 l (0.154-0.298) in group A (regular tiotropium and add-on formoterol) and 0.228 l (0.165-0.291) in group B (regular formoterol and add-on tiotropium). The mean maximal change in FEV1 over pre-inhalation of the second drug value was 0.081 l (95% CI, 0.029-0.133) after tiotropium → formoterol and 0.054 l (95% CI, 0.016-0.092) after formoterol → tiotropium. The mean maximal change in FVC over baseline was 0.519 l (95% CI, 0.361-0.676) in group A and 0.495 l (95% CI, 0.307-0.683) in group B. The mean maximal change in FVC over pre-inhalation of the second drug value was 0.159 l (95% CI, 0.048-0.270) after tiotropium-formoterol and 0.175 l (95% CI, 0.083-0.266) after formoterol → tiotropium.<img src="6v41nSupl.2-13084073tab06.gif"></img>Fig. 6. Mean response curves following the sequential inhalation of tiotropium (Tio) and formoterol (For) for FEV1 and FVC. Arrow indicates the administration of the second drug. *p < 0.05; **p < 0.01; ***p < 0.001 in the sequence tiotropium → formoterol. §p < 0.05; §§p < 0.01; §§§p < 0.001 in the sequence formoterol → tiotropium. (Data from Cazzola et al54.) These results suggest that supplementing a second different long-acting bronchodilator to a regularly administered long-acting bronchodilator seems to be to the patient's advantage in terms of bronchodilation. We cannot exclude that the greater bronchodilatory response that we observed when a second bronchodilator was given after the first one may be justified by a carry over effect, considering that both formoterol and tiotropium are long-lasting bronchodilators. Nonetheless, it is well know that the mean peak bronchodilation with both formoterol and tiotropium in COPD patients is reached after two to three hours43 and we have documented that the addition of a second bronchodilator three hours after the inhalation of the first agent, could amplify the maximum bronchodilation of the first agent. This result seems to be important because it indicates the possibility that a patient who is unable to perceive bronchodilation or must perform an exercise could use a second long-acting bronchodilator that will assure a long-lasting effect. In any case, it must be highlighted that significant improvement in pulmonary function has been achieved by adding tiotropium or formoterol at the recommended dosages in patients already in regular treatment with formoterol or tiotropium, respectively, with no statistically significant difference between the different sequences. This finding supports Rennard's opinion3 that treatment can be initiated with an agent from any of the available classes. If symptomatic control is inadequate, an agent from another class can be added. ConclusionsAt present time, there is no clear documentation that tiotropium is superior to formoterol or the contrary. At the recommend doses for COPD therapy, formoterol twice daily and tiotropium once daily induce comparable night time bronchodilation after regular treatment49.A combination of tiotropium and a long-acting β2-AR agonist is more effective than single drugs alone in inducing bronchodilation and bronchodilator-mediated symptom benefit in patients suffering from COPD42,43,49,51. Add-on therapy of formoterol in the morning to maintenance therapy with tiotropium significantly improves FEV1 and IC for more than twelve hours in patients with moderate-to-severe COPD51. Add-on therapy of a second formoterol dose administered in the evening produces a further increase in average FEV1 and IC, but not in trough IC51. All these findings support, in our opinion, the possibility of combining tiotropium and formoterol, and likely salmeterol, in patients suffering from stable COPD, but exclude the once-daily administration of the two drugs in combination within a single inhaler. It must be determined yet whether tiotropium is more effective when administered in the evening compared with morning dosing, in view of the circadian variation of bronchial tone. Because long-acting β2-AR agonists are given twice daily but tiotropium bromide is required only once daily, the challenge is now to develop a combined inhaler that can be employed on a once daily basis. The incorporation of once daily dosing is an important strategy to improve compliance since it is a regime preferred by most patients.<hr></hr> Correspondencia: M. Cazzola. Via del Parco Margherita, 24. 80121 Napoli. Italy. E-mail: <a href="mailto:mcazzola@qubisoft.it" class="elsevierStyleCrossRefs"> mcazzola@qubisoft.it</a>" "pdfFichero" => "6v41nSupl.2a13084073pdf001.pdf" "tienePdf" => true "multimedia" => array:12 [ 0 => array:8 [ "identificador" => "tbl1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tablaImagen" => array:1 [ 0 => array:4 [ "imagenFichero" => "6v41nSupl.2-13084073tab01.gif" "imagenAlto" => 936 "imagenAncho" => 1086 "imagenTamanyo" => 60712 ] ] ] ] ] "descripcion" => array:1 [ "en" => "Schematic presentation of the potential alternative role of β2-adrenoceptor (AR) in the pre-synaptic control of acetylcholine (ACh) release from airway parasympathetic nerve endings. A: circulating adrenaline; β2-AR: β2-adrenoceptor; M1 and M3: muscarinic M1 or M3 receptors; (>: neuronal activity; →: stimulatory effect; (=↓: inhibitory effect." ] ] 1 => array:8 [ "identificador" => "tbl2" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tablaImagen" => array:1 [ 0 => array:4 [ "imagenFichero" => "6v41nSupl.2-13084073tab02.gif" "imagenAlto" => 1532 "imagenAncho" => 1083 "imagenTamanyo" => 50576 ] ] ] ] ] "descripcion" => array:1 [ "en" => "Mean changes (± SE) in FEV1 (l) from pre-dosing value on each of the dosing days up to 90 min (A) and up to 24 h (B) after inhalation of formoterol 12 μg (FOR), tiotropium 18 μg (TIO), and tiotropium 18 μg + formoterol 12 μg (TIO + FOR). *p < 0.05; **p < 0.01; ***p < 0.001 versus baseline. (Data from Cazzola et al42.)" ] ] 2 => array:8 [ "identificador" => "tbl3" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tablaImagen" => array:1 [ 0 => array:4 [ "imagenFichero" => "6v41nSupl.2-13084073tab03.gif" "imagenAlto" => 1535 "imagenAncho" => 1083 "imagenTamanyo" => 52741 ] ] ] ] ] "descripcion" => array:1 [ "en" => "Mean changes (± SE) in FEV1 (l) from pre-dosing value on each of the dosing days up to 90 min (A) and up to 24 h (B) after inhalation of salmeterol 50 μg (SALM), tiotropium 18 μg (TIO), and salmeterol 50 μg + tiotropium 18 μg (SALM + TIO). *p < 0.05; **p < 0.01; ***p < 0.001 versus baseline. (Data from Cazzola et al43.)" ] ] 3 => array:8 [ "identificador" => "tbl4" "etiqueta" => "Fig. 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tablaImagen" => array:1 [ 0 => array:4 [ "imagenFichero" => "6v41nSupl.2-13084073tab04.gif" "imagenAlto" => 891 "imagenAncho" => 1083 "imagenTamanyo" => 25691 ] ] ] ] ] "descripcion" => array:1 [ "en" => "Tiotropium 18 μg once daily (TIO qd), tiotropium 18 μg once daily + add-on formoterol 12 μg once daily (TIO + FORM qd) and tiotropium 18 μg once daily + add-on formoterol 12 μg twice daily (TIO + FORM bid) FEV1 AUCs calculated using the trapezoidal rule divided by the corresponding observation time to report in ml units. ap < 0.05 versus formoterol; bp < 0.05 versus tiotropium. (Data from van Noord et al49.)" ] ] 4 => array:8 [ "identificador" => "tbl5" "etiqueta" => "Fig. 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tablaImagen" => array:1 [ 0 => array:4 [ "imagenFichero" => "6v41nSupl.2-13084073tab05.gif" "imagenAlto" => 889 "imagenAncho" => 1079 "imagenTamanyo" => 26911 ] ] ] ] ] "descripcion" => array:1 [ "en" => "Tiotropium 18 μg once daily (TIO qd), formoterol 12 μg twice daily (FORM bid) and tiotropium 18 μg + formoterol 12 μg once daily (TIO + FORM qd) FEV1 AUCs calculated using the trapezoidal rule divided by the corresponding observation time to report in ml units. ap < 0.05 versus formoterol; bp < 0.05 versus tiotropium. (Data from van Noord et al51.)" ] ] 5 => array:8 [ "identificador" => "tbl6" "etiqueta" => "Fig. 6" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tablaImagen" => array:1 [ 0 => array:4 [ "imagenFichero" => "6v41nSupl.2-13084073tab06.gif" "imagenAlto" => 1514 "imagenAncho" => 1091 "imagenTamanyo" => 42534 ] ] ] ] ] "descripcion" => array:1 [ "en" => "Mean response curves following the sequential inhalation of tiotropium (Tio) and formoterol (For) for FEV1 and FVC. Arrow indicates the administration of the second drug. *p < 0.05; **p < 0.01; ***p < 0.001 in the sequence tiotropium → formoterol. §p < 0.05; §§p < 0.01; §§§p < 0.001 in the sequence formoterol → tiotropium. (Data from Cazzola et al54.)" ] ] 6 => array:5 [ "identificador" => "tbl7" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" ] 7 => array:5 [ "identificador" => "tbl8" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" ] 8 => array:5 [ "identificador" => "tbl9" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" ] 9 => array:5 [ "identificador" => "tbl10" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" ] 10 => array:5 [ "identificador" => "tbl11" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" ] 11 => array:5 [ "identificador" => "tbl12" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:54 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2003 [accessed Dec 23, 2004]. Available at: http://www.goldcopd.com" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2003 [accessed Dec 23, 2004]. Available at: http://www.goldcopd.com" "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Global Initiative for Chronic Obstructive Lung Disease." ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Standards for the diagnosis and management of patients with COPD [accessed Dec 23, 2004]. Available at: http://www.thoracic.org" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Standards for the diagnosis and management of patients with COPD [accessed Dec 23, 2004]. Available at: http://www.thoracic.org" "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "American Thoracic Society/European Respiratory Society." ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Treatment of stable chronic obstructive pulmonary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Rennard SI." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(04)16941-9" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2004" "volumen" => "364" "paginaInicial" => "791" "paginaFinal" => "802" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15337408" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004;117 Suppl 1:24-32." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004;117 Suppl 1:24-32." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Barnes PJ." ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Neural regulation of airway smooth muscle tone." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Canning BJ" 1 => "Fischer A." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Respir Physiol" "fecha" => "2001" "volumen" => "125" "paginaInicial" => "113" "paginaFinal" => "27" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11240156" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effective site of bronchodilation by β-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease: direct measurement of intrabronchial pressure with a new catheter." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Ohrui T" 1 => "Yanai M" 2 => "Sekiwzawa K" 3 => "Morikawa M" 4 => "Sasaki H" 5 => "Takishima T." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm/146.1.88" "Revista" => array:6 [ "tituloSerie" => "Am Rev Respir Dis" "fecha" => "1992" "volumen" => "146" "paginaInicial" => "88" "paginaFinal" => "91" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1626821" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Ultrastructural studies on the neuromuscular control of human tracheal and bronchial muscle." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Daniel EE" 1 => "Kannan M" 2 => "Davis C" 3 => "Posey-Daniel V." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Respir Physiol" "fecha" => "1986" "volumen" => "63" "paginaInicial" => "109" "paginaFinal" => "28" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3952384" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Inhibition of cholinergic neurotransmission in human airways by β2-adrenoceptors." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Rhoden KJ" 1 => "Meldrum LA" 2 => "Barnes PJ." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Appl Physiol" "fecha" => "1988" "volumen" => "65" "paginaInicial" => "700" "paginaFinal" => "5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2844715" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "β-adrenoceptors mediate inhibition of [3H]-acetylcholine release from the isolated rat and guinea-pig trachea: role of the airway mucosa and prostaglandins." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Wessler I" 1 => "Reinheimer T" 2 => "Brunn G" 3 => "Anderson GP" 4 => "Maclagan J" 5 => "Racké K." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Pharmacol" "fecha" => "1994" "volumen" => "113" "paginaInicial" => "1221" "paginaFinal" => "30" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7889276" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "β2-Adrenoceptor activation augments acetylcholine release from tracheal parasympathetic nerves." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Zhang XY" 1 => "Olszewski MA" 2 => "Robinson NE." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Physiol" "fecha" => "1995" "volumen" => "268" "paginaInicial" => "L950" "paginaFinal" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7611436" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenaline." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Belvisi MG" 1 => "Patel HJ" 2 => "Takahashi T" 3 => "Barnes PJ" 4 => "Giembycz MA." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Pharmacol" "fecha" => "1996" "volumen" => "117" "paginaInicial" => "1413" "paginaFinal" => "20" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8730733" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Enhancement of endogenous acetylcholine and norepinephrine release by prejunctional β2-adrenoceptors in human isolated bronchi [abstract]." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "De Haas JR.A" 1 => "Terpstra JS" 2 => "Zaagsma J" 3 => "Roffel AF." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "1998" "volumen" => "157" "paginaInicial" => "723A" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effects of enantiomers of β2-agonists on ACh release and smooth muscle contraction in the trachea." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Zhang XY" 1 => "Zhu FX" 2 => "Olszewski MA" 3 => "Robinson NE." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Am J Physiol" "fecha" => "1998" "volumen" => "274" "paginaInicial" => "32L" "paginaFinal" => "8L" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Facilitatory β2-adrenoceptors on cholinergic and adrenergic nerve endings of the guinea pig trachea." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "De Haas JR" 1 => "Terpstra JS" 2 => "Van der Zwaag M" 3 => "Kockelbergh PG" 4 => "Roffel AF" 5 => "Zaagsma J." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Am J Physiol Lung Cell Mol Physiol" "fecha" => "1999" "volumen" => "276" "paginaInicial" => "L420" "paginaFinal" => "5" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Kume H" 1 => "Graziano MP" 2 => "Kotlikoff MI." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Proc Natl Acad Sci USA" "fecha" => "1992" "volumen" => "89" "paginaInicial" => "11051" "paginaFinal" => "5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1438313" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Inhibition of cholinergic neurotransmission in guinea pig trachea by NS1619, a putative activator of large-conductance, calcium-activated potassium channels." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Patel HJ" 1 => "Giembycz MA" 2 => "Keeling JE" 3 => "Barnes PJ" 4 => "Belvisi MG." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Pharmacol Exp Ther" "fecha" => "1998" "volumen" => "286" "paginaInicial" => "952" "paginaFinal" => "8" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9694955" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Modulation of cholinergic responsiveness through the β-adrenoceptor signal transmission pathway in bovine trachealis." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Brichetto L" 1 => "Song P" 2 => "Crimi E" 3 => "Rehder K" 4 => "Brusasco V." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1152/japplphysiol.00028.2003" "Revista" => array:6 [ "tituloSerie" => "J Appl Physiol" "fecha" => "2003" "volumen" => "95" "paginaInicial" => "735" "paginaFinal" => "41" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12730144" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Dorinsky PM" 1 => "Reisner C" 2 => "Ferguson GT" 3 => "Menjoge SS" 4 => "Serby CW" 5 => "Witek TJ Jr." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "1999" "volumen" => "115" "paginaInicial" => "966" "paginaFinal" => "71" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10208193" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A comparison of the bronchodilating effects of a β-adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Easton PA" 1 => "Jadue C" 2 => "Dhingra S" 3 => "Anthonisen NR." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM198609183151205" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1986" "volumen" => "315" "paginaInicial" => "735" "paginaFinal" => "9" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2943994" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "LeDoux EJ" 1 => "Morris JF" 2 => "Temple WP" 3 => "Duncan C." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "1989" "volumen" => "95" "paginaInicial" => "1013" "paginaFinal" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2523291" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "COMBIVENT Inhalation Aerosol Study Group." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "1994" "volumen" => "105" "paginaInicial" => "1411" "paginaFinal" => "9" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8181328" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Addition of anticholinergic solution prolongs bronchodilator effect of β2 agonists in patients with chronic obstructive pulmonary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Levin DC" 1 => "Little KS" 2 => "Laughlin KR" 3 => "Galbraith JM" 4 => "Gustman PM" 5 => "Murphy D" 6 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Med" "fecha" => "1996" "volumen" => "100" "paginaInicial" => "40S" "paginaFinal" => "8S" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8610716" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Routine nebulized ipratropium and albuterol together are better than either alone in COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "COMBIVENT Inhalation Solution Study Group." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "1997" "volumen" => "112" "paginaInicial" => "1514" "paginaFinal" => "21" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9404747" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Friedman M" 1 => "Serby CW" 2 => "Menjoge SS" 3 => "Wilson JD" 4 => "Hilleman DE" 5 => "Witek TJ Jr." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "1999" "volumen" => "115" "paginaInicial" => "635" "paginaFinal" => "41" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10084468" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Cazzola M" 1 => "Santangelo G" 2 => "Piccolo A" 3 => "Salzillo A" 4 => "Matera MG" 5 => "D'Amato G" 6 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Pulm Pharmacol" "fecha" => "1994" "volumen" => "7" "paginaInicial" => "103" "paginaFinal" => "7" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7915921" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Efficacy of salmeterol xinafoate in the treatment of COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Mahler DA" 1 => "Donohue JF" 2 => "Barbee RA" 3 => "Goldman MD" 4 => "Gross NJ" 5 => "Wisniewski ME" 6 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "1999" "volumen" => "115" "paginaInicial" => "957" "paginaFinal" => "65" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10208192" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Rennard SI" 1 => "Anderson W" 2 => "ZuWallack R" 3 => "Broughton J" 4 => "Bailey W" 5 => "Friedman M" 6 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.163.5.9903053" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2001" "volumen" => "163" "paginaInicial" => "1087" "paginaFinal" => "92" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11316640" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Dahl R" 1 => "Greefhorst LA" 2 => "Nowak D" 3 => "Nonikov V" 4 => "Byrne AM" 5 => "Thomson MH" 6 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.164.5.2007006" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2001" "volumen" => "164" "paginaInicial" => "778" "paginaFinal" => "84" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11549532" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Matera MG" 1 => "Caputi M" 2 => "Cazzola M." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Respir Med" "fecha" => "1996" "volumen" => "90" "paginaInicial" => "497" "paginaFinal" => "9" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8869445" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Sichletidis L" 1 => "Kottakis J" 2 => "Marcou S" 3 => "Constantinidis TC" 4 => "Antoniades A." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Clin Pract" "fecha" => "1999" "volumen" => "53" "paginaInicial" => "185" "paginaFinal" => "8" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10665129" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Ikeda A" 1 => "Nishimura K" 2 => "Koyama H" 3 => "Izumi T." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "1995" "volumen" => "50" "paginaInicial" => "62" "paginaFinal" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7886652" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Cazzola M" 1 => "Matera MG" 2 => "Di Perna E" 3 => "Califano C" 4 => "D'Amato M" 5 => "Mazzarella G." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Respir Med" "fecha" => "1999" "volumen" => "93" "paginaInicial" => "909" "paginaFinal" => "11" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10653054" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Cazzola M" 1 => "Di Perna F" 2 => "Centanni S" 3 => "Califano C" 4 => "Donner CF" 5 => "D'Amato M" 6 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "1999" "volumen" => "54" "paginaInicial" => "1083" "paginaFinal" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10567627" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Van Noord JA" 1 => "De Munck DR" 2 => "Bantje TA" 3 => "Hop WC" 4 => "Akveld ML" 5 => "Bommer AM." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2000" "volumen" => "15" "paginaInicial" => "878" "paginaFinal" => "85" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10853852" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib35" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "D'Urzo AD" 1 => "De Salvo MC" 2 => "Ramírez-Rivera A" 3 => "Almeida J" 4 => "Sichletidis L" 5 => "Rapatz G" 6 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "2001" "volumen" => "119" "paginaInicial" => "1347" "paginaFinal" => "56" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11348938" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib36" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease. Am J Med. 2004;117 Suppl 1:33-40." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease. Am J Med. 2004;117 Suppl 1:33-40." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Casaburi R" 1 => "Conoscenti CS." ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib37" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Tennant RC" 1 => "Erin EM" 2 => "Barnes PJ" 3 => "Hansel TT." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "-adrenoceptor agonists or tiotropium bromide for patients with COPD:is combination therapy justified? Curr Opin Pharmacol" "fecha" => "2003" "volumen" => "3" "paginaInicial" => "270" "paginaFinal" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12810191" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib38" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The role of long-acting bronchodilators in the management of stable COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Tashkin DP" 1 => "Cooper CB." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "2004" "volumen" => "125" "paginaInicial" => "249" "paginaFinal" => "59" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14718448" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib39" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Long-acting bronchodilators are the first-choice option for the treatment of stable COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Cazzola M" 1 => "Matera MG." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "2004" "volumen" => "125" "paginaInicial" => "9" "paginaFinal" => "11" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14718412" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib40" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Donohue JF" 1 => "Van Noord JA" 2 => "Bateman ED" 3 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "2002" "volumen" => "122" "paginaInicial" => "47" "paginaFinal" => "55" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12114338" "web" => "Medline" ] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib41" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Brusasco V" 1 => "Hodder R" 2 => "Miravitlles M" 3 => "Korducki L" 4 => "Towse L" 5 => "Kesten S." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2003" "volumen" => "58" "paginaInicial" => "399" "paginaFinal" => "404" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12728159" "web" => "Medline" ] ] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib42" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Cazzola M" 1 => "Di Marco F" 2 => "Santus P" 3 => "Boveri B" 4 => "Verga M" 5 => "Matera MG" 6 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Pulm Pharmacol Ther" "fecha" => "2004" "volumen" => "17" "paginaInicial" => "35" "paginaFinal" => "9" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14643169" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib43" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "The functional impact of adding salmeterol and tiotropium in patients with stable COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Cazzola M" 1 => "Centanni S" 2 => "Santus P" 3 => "Verga M" 4 => "Mondoni M" 5 => "Di Marco F" 6 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Respir Med" "fecha" => "2004" "volumen" => "98" "paginaInicial" => "1214" "paginaFinal" => "21" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15588043" "web" => "Medline" ] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib44" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Takahashi T" 1 => "Belvisi MG" 2 => "Patel H" 3 => "Ward JK" 4 => "Tadjkarimi S" 5 => "Yacoub MH" 6 => "et al." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.150.6.7952627" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "1994" "volumen" => "150" "paginaInicial" => "1640" "paginaFinal" => "5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7952627" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib45" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Anderson P" 1 => "Lotvall J" 2 => "Linden A." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Lung" "fecha" => "1996" "volumen" => "174" "paginaInicial" => "159" "paginaFinal" => "70" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8830192" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib46" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effects of salmeterol on muscarinic inhibition of adenylyl cyclase in bovine trachealis cells." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Ethier MF" 1 => "Dextradeur T" 2 => "Schaefer OP" 3 => "Madison JM." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Life Sci" "fecha" => "2000" "volumen" => "67" "paginaInicial" => "2753" "paginaFinal" => "8" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11105991" "web" => "Medline" ] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib47" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Teschemacher A" 1 => "Reinhardt D" 2 => "Lemoine H." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "-sympathomimetics contribute to their relaxant effects in airway smooth muscle cells? Pulm Pharmacol Ther" "fecha" => "1998" "volumen" => "11" "paginaInicial" => "253" "paginaFinal" => "61" ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib48" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Van Noord JA" 1 => "Smeets JJ" 2 => "Custers FL" 3 => "Korducki L" 4 => "Cornelissen PJ." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2002" "volumen" => "19" "paginaInicial" => "639" "paginaFinal" => "44" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11998992" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib49" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]. Am J Respir Crit Care Med. 2003;167 Suppl 7:320A." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]. Am J Respir Crit Care Med. 2003;167 Suppl 7:320A." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Van Noord JA" 1 => "Aumann J" 2 => "Janssens E" 3 => "Mueller A" 4 => "Cornelissen PJG." ] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib50" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Effects of two bronchodilatators." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Gaultier C" 1 => "Reinberg A" 2 => "Girard E Circadian rhythms in lung resistance and dynamic lung compliance of healthy children." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Respir Physiol" "fecha" => "1977" "volumen" => "3l" "paginaInicial" => "169" "paginaFinal" => "82" ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib51" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods [abstract]. Am J Respir Crit Care Med. 2003;167 Suppl 7:95A." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods [abstract]. Am J Respir Crit Care Med. 2003;167 Suppl 7:95A." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Van Noord JA" 1 => "Aumann J" 2 => "Janssens E" 3 => "Folgering H" 4 => "Mueller A" 5 => "Cornelissen PJG." ] ] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib52" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Combination bronchodilator therapy in COPD. Chest. 1995;107 Suppl:171-5." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Combination bronchodilator therapy in COPD. Chest. 1995;107 Suppl:171-5." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Rennard SI." ] ] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib53" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Cazzola M" 1 => "Di Perna F" 2 => "Califano C" 3 => "Vinciguerra A" 4 => "D'Amato M." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1006/pupt.1999.0208" "Revista" => array:6 [ "tituloSerie" => "Pulm Pharmacol Ther" "fecha" => "1999" "volumen" => "12" "paginaInicial" => "267" "paginaFinal" => "71" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10501652" "web" => "Medline" ] ] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib54" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med. In press 2005." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med. In press 2005." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Cazzola M" 1 => "Noschese P" 2 => "Salzillo A" 3 => "De Giglio C" 4 => "D'Amato G" 5 => "Matera MG." ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/03002896/00000041000000S2/v0_201307091044/13084073/v0_201307091045/en/main.assets" "Apartado" => array:4 [ "identificador" => "14663" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Controversias en el tratamiento farmacológico de la EPOC" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/03002896/00000041000000S2/v0_201307091044/13084073/v0_201307091045/en/6v41nSupl.2a13084073pdf001.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13084073?idApp=UINPBA00003Z"]

Statistics

M. Cazzolaa, MG. Materab, KM. O'Donnellc

a Unit of Pneumology and Allergology. Department of Respiratory Medicine. A. Cardarelli Hospital. Naples.

b Unit of Pharmacology. Department of Experimental Medicine. Second University. Naples. Italy.

c Unit of Respiratory Medicine. Department of Internal Medicine. University of Rome Tor Vergata. Rome. Italy.

Read

11382

Times
was read the article

2104

Total PDF

9278

Total HTML

Share statistics

 array:20 [
  "pii" => "13084073"
  "issn" => "03002896"
  "doi" => "10.1016/S0210-5705(09)71003-9"
  "estado" => "S300"
  "fechaPublicacion" => "2005-05-15"
  "documento" => "article"
  "crossmark" => 0
  "subdocumento" => "fla"
  "cita" => "Arch Bronconeumol. 2005;41 Supl 2:24-31"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 7222
    "formatos" => array:3 [
      "EPUB" => 101
      "HTML" => 6417
      "PDF" => 704
    ]
  ]
  "itemSiguiente" => array:16 [
    "pii" => "13084074"
    "issn" => "03002896"
    "doi" => "10.1016/S0210-5705(09)71003-9"
    "estado" => "S300"
    "fechaPublicacion" => "2005-05-15"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Arch Bronconeumol. 2005;41 Supl 2:32-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 10408
      "formatos" => array:3 [
        "EPUB" => 76
        "HTML" => 9774
        "PDF" => 558
      ]
    ]
    "es" => array:9 [
      "idiomaDefecto" => true
      "titulo" => "Controversias farmacol&#243;gicas reflejadas en las gu&#237;as y normativas nacionales e internacionales"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "32"
          "paginaFinal" => "37"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Pharmacological controversies reflected in national and international guidelines and recommendations"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "P de Lucas Ramos, JM Rodr&#237;guez Gonz&#225;lez-Moro, S L&#243;pez Mart&#237;n"
          "autores" => array:3 [
            0 => array:2 [
              "Iniciales" => "P"
              "apellidos" => "de Lucas Ramos"
            ]
            1 => array:2 [
              "Iniciales" => "JM"
              "apellidos" => "Rodr&#237;guez Gonz&#225;lez-Moro"
            ]
            2 => array:2 [
              "Iniciales" => "S"
              "apellidos" => "L&#243;pez Mart&#237;n"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13084074?idApp=UINPBA00003Z"
    "url" => "/03002896/00000041000000S2/v0_201307091044/13084074/v0_201307091046/es/main.assets"
  ]
  "itemAnterior" => array:16 [
    "pii" => "13084072"
    "issn" => "03002896"
    "doi" => "10.1016/S0210-5705(09)71003-9"
    "estado" => "S300"
    "fechaPublicacion" => "2005-05-15"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Arch Bronconeumol. 2005;41 Supl 2:21-3"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6905
      "formatos" => array:3 [
        "EPUB" => 107
        "HTML" => 6257
        "PDF" => 541
      ]
    ]
    "es" => array:9 [
      "idiomaDefecto" => true
      "titulo" => "Corticoides inhalados&#58; &#191;a qui&#233;n y cu&#225;ndo&#63;"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "21"
          "paginaFinal" => "23"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Inhaled corticosteroids&#58; which patients and when&#63;"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "P Casan Clar&#224;"
          "autores" => array:1 [
            0 => array:2 [
              "Iniciales" => "P"
              "apellidos" => "Casan Clar&#224;"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13084072?idApp=UINPBA00003Z"
    "url" => "/03002896/00000041000000S2/v0_201307091044/13084072/v0_201307091045/es/main.assets"
  ]
  "en" => array:11 [
    "idiomaDefecto" => true
    "titulo" => "Association of &#946; <span class="elsevierStyleInf">2</span>-adrenergic agonists and tiotropium&#58; is the combination justified&#63;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "24"
        "paginaFinal" => "31"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "M Cazzola, MG Matera, KM O&#39;Donnell"
        "autores" => array:3 [
          0 => array:3 [
            "Iniciales" => "M"
            "apellidos" => "Cazzola"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "Iniciales" => "MG"
            "apellidos" => "Matera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "Iniciales" => "KM"
            "apellidos" => "O&#39;Donnell"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => "Unit of Pneumology and Allergology. Department of Respiratory Medicine. A. Cardarelli Hospital. Naples."
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Unit of Pharmacology. Department of Experimental Medicine. Second University. Naples. Italy."
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Unit of Respiratory Medicine. Department of Internal Medicine. University of Rome Tor Vergata. Rome. Italy."
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Association of &#946; <span class="elsevierStyleInf">2</span>-adrenergic agonists and tiotropium&#58; is the combination justified&#63;"
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold"> Introduction</span></p><p class="elsevierStylePara"> Current treatment for chronic obstructive pulmonary disease &#40;COPD&#41; is aimed at increasing airflow&#44; decreasing respiratory symptoms &#40;particularly dyspnea&#41;&#44; decreasing exacerbations&#44; and improving the quality of life&#46; Consequently&#44; it not surprising that both the Global Initiative for Obstructive Lung Disease &#40;GOLD&#41; guidelines<span class="elsevierStyleSup">1</span>&#44; and the recent American Thoracic Society &#40;ATS&#41;&#47;European Respiratory Society &#40;ERS&#41; position paper for the diagnosis and treatment of patients with COPD<span class="elsevierStyleSup">2</span> emphasize the role of bronchodilators in symptomatic management of all stages of COPD&#46;</p><p class="elsevierStylePara"> There are two primary pharmacologic classes of inhaled bronchodilators with different mechanisms of action which are used in the treatment of COPD&#58; &#946;<span class="elsevierStyleInf">2</span>-adrenoceptor &#40;&#946;<span class="elsevierStyleInf">2</span>-AR&#41; agonists and quarternary ammonium anticholinergic agents<span class="elsevierStyleSup">3</span>&#44; which can be either short-acting &#40;e&#46;g&#46;&#44; salbutamol&#44; terbutaline&#44; ipratropium or oxitropium&#41; or long-acting &#40;e&#46;g&#46;&#44; formoterol&#44; salmeterol&#44; or tiotropium&#41;&#46; Both the GOLD Update and the ATS&#47;ERS position paper recommend&#44; for moderate-to-very severe COPD&#44; use of regular treatment with long-acting bronchodilators rather than short acting bronchodilators&#44; with the choice depending on the availability of medication and the patient&#39;s response<span class="elsevierStyleSup">1&#44;2</span>&#46;</p><p class="elsevierStylePara">For patients whose conditions are not sufficiently controlled by monotherapy&#44; these guidelines highlight that combining medications of different classes&#44; in particular an inhaled anticholinergic with a &#946;<span class="elsevierStyleInf">2</span>-AR agonist&#44; seems a convenient way of delivering treatment and obtaining better results<span class="elsevierStyleSup">1&#44;2</span>&#46; This includes better lung function and improved symptoms&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Rationale for combining</span> &#946;<span class="elsevierStyleBold"><span class="elsevierStyleInf">2</span>-adrenoceptor agonists and anticholinergic agents</span></p><p class="elsevierStylePara"> Postganglionic&#44; parasympathetic-cholinergic nerves innervate the airways&#46; When activated&#44; these nerves are capable of obliterating the lumen of small bronchi and bronchioles&#44; and markedly increasing airway resistance in larger&#44; cartilaginous airways&#44; by secretion of the bronchoconstricting mediator acetylcholine &#40;ACh&#41;&#44; which causes activation of muscarinic receptors at the level of the target cells&#44; such as bronchial smooth muscle and goblet cells<span class="elsevierStyleSup">4</span>&#46; Conversely&#44; sympathetic nerves may control tracheobronchial blood vessels&#44; but no innervation of human airway smooth muscle has been demonstrated&#46; &#946;<span class="elsevierStyleInf">2</span>-ARs&#44; however&#44; are abundantly expressed on human airway smooth muscle and activation of these receptors causes its relaxation<span class="elsevierStyleSup">5</span>&#46;</p><p class="elsevierStylePara"> Bronchodilatation may&#44; therefore&#44; be obtained either by stimulating the &#946;<span class="elsevierStyleInf">2</span>-ARs with &#946;<span class="elsevierStyleInf">2</span>-AR agonists&#44; or by inhibiting the action of ACh at muscarinic receptors with anticholinergic agents&#46; In any case&#44; anticholinergics are more likely to decrease central airway resistance&#44; although there are muscarinic receptors that are expressed in the smooth muscle of small airways which do not appear to be innervated by cholinergic nerves&#44; and &#946;<span class="elsevierStyleInf">2</span>-AR agonists have a greater effect on peripheral airway resistance in patients with COPD<span class="elsevierStyleSup">6</span>&#46; It is reasonable to postulate that attempts to reduce bronchoconstriction through two distinct mechanisms &#40;anticholinergic and sympathomimetic&#41; with a different prevalent site of action may maximize bronchodilator response&#46;</p><p class="elsevierStylePara"> Interestingly&#44; the presence of small dense-cored vesicles containing adrenergic nerve varicosities&#44; occasionally in close proximity to morphologically characteristic cholinergic nerve-endings&#44; has been identified in human airways<span class="elsevierStyleSup">7</span>&#44; suggesting that catecholamines might modulate cholinergic neurotransmission &#40;fig&#46; 1&#41;&#46; However&#44; different studies have led to dissimilar conclusions&#46; Early research papers based on force measurement alone suggested that stimulation of &#946;<span class="elsevierStyleInf">2</span>-ARs inhibits cholinergic neurotransmission<span class="elsevierStyleSup">8</span>&#44; most probably by the release of inhibitory prostaglandins from the airway mucosa<span class="elsevierStyleSup">9</span>&#46; However&#44; interpretation of these data is seriously hampered by the large postjunctional effects of &#946;<span class="elsevierStyleInf">2</span>-AR agonists&#46; Zhang et al<span class="elsevierStyleSup">10</span> were the first to report an excitatory &#946;<span class="elsevierStyleInf">2</span>-AR in airway parasympathetic nerves&#46; After their report in studies on the horse&#44; this receptor was subsequently reported in guinea pigs<span class="elsevierStyleSup">11</span> and in human airway parasympathetic nerves<span class="elsevierStyleSup">12</span>&#46; Activation of &#946;<span class="elsevierStyleInf">2</span>-ARs by isoproterenol&#44; by the racemic mixture of specific &#946;<span class="elsevierStyleInf">2</span>-AR agonists such as salbutamol and formoterol or by <span class="elsevierStyleItalic">R</span>-enantiomers of &#946;<span class="elsevierStyleInf">2</span>-agonists can increase ACh release in a concentration-dependent manner<span class="elsevierStyleSup">13</span>&#46; Consistent with the results of &#946;<span class="elsevierStyleInf">2</span>-AR stimulation<span class="elsevierStyleSup">14</span>&#44; direct activation of the &#946;<span class="elsevierStyleInf">2</span>-AR-coupled G<span class="elsevierStyleInf">s</span> protein by cholera toxin&#44; which increases the activity of adenylyl cyclase&#44; caused an increase in ACh release in epithelium-denuded guinea pig trachealis<span class="elsevierStyleSup">11</span>&#46; In airway smooth muscle cells&#44; however&#44; stimulation of G<span class="elsevierStyleInf">s</span> protein directly opens large Ca<span class="elsevierStyleSup">2&#43;</span>-activated potassium &#40;K<span class="elsevierStyleInf">Ca</span>&#41; channels<span class="elsevierStyleSup">15</span>&#44; which has been found to decrease ACh release in guinea pig trachealis<span class="elsevierStyleSup">16</span>&#46; Recently&#44; Brichetto et al<span class="elsevierStyleSup">17</span> have confirmed that &#946;<span class="elsevierStyleInf">2</span>-AR agonists attenuate cholinergic neurotransmission in the isolated bovine trachealis model and this happens by a mechanism not involving cAMP but K<span class="elsevierStyleInf">Ca</span> channels&#46;</p><p class="elsevierStylePara"><img src="6v41nSupl.2-13084073tab01.gif"></img></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Fig&#46; 1&#46; Schematic presentation of the potential alternative role of</span> &#946;<span class="elsevierStyleBold"><span class="elsevierStyleInf">2</span>-adrenoceptor &#40;AR&#41; in the pre-synaptic control of acetylcholine &#40;ACh&#41; release from airway parasympathetic nerve endings&#46; A&#58; circulating adrenaline&#59;</span> &#946;<span class="elsevierStyleBold"><span class="elsevierStyleInf">2</span>-AR&#58;</span> &#946;<span class="elsevierStyleBold"><span class="elsevierStyleInf">2</span>-adrenoceptor&#59; M<span class="elsevierStyleInf">1</span> and M<span class="elsevierStyleInf">3</span>&#58; muscarinic M<span class="elsevierStyleInf">1</span> or M<span class="elsevierStyleInf">3</span> receptors&#59; &#40;</span>&#62;<span class="elsevierStyleBold">&#58; neuronal activity&#59;</span> &#8594;<span class="elsevierStyleBold">&#58; stimulatory effect&#59; &#40;</span>&#61;&#8595;<span class="elsevierStyleBold">&#58; inhibitory effect&#46;</span></p><p class="elsevierStylePara"> Whatever the type of interaction between the two systems may be&#44; combining &#946;<span class="elsevierStyleInf">2</span>-AR agonists and anticholinergic agents is pharmacologically useful&#46; In fact&#44; in the first case&#44; the addition of a &#946;<span class="elsevierStyleInf">2</span>-AR agonist decreases the release of ACh because of the modulation of cholinergic neurotransmission by prejunctional &#946;<span class="elsevierStyleInf">2</span>-ARs and&#44; consequently&#44; amplifies the bronchial smooth muscle relaxation directly induced by the anticholinergic agent&#46; On the contrary&#44; in the second circumstance&#44; the addition of an anticholinergic agent can reduce the peripheral bronchoconstrictor effects of ACh&#44; whose release has been facilitated by the &#946;<span class="elsevierStyleInf">2</span>-AR agonist&#44; and in this manner can amplify the bronchodilation elicited by the &#946;<span class="elsevierStyleInf">2</span>-AR agonist through the direct stimulation of smooth muscle &#946;<span class="elsevierStyleInf">2</span>-ARs&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Combination therapy with ipratropium and a</span> &#946;<span class="elsevierStyleBold"><span class="elsevierStyleInf">2</span>-agonist</span></p><p class="elsevierStylePara">It has been documented that standard doses of short acting &#946;<span class="elsevierStyleInf">2</span>-agonists do not give optimal results in patients with COPD and that an anticholinergic agent gives additional bronchodilation<span class="elsevierStyleSup">18</span>&#46; In addition&#44; the reproducibility of responsiveness to bronchodilators in patients with COPD is improved when the pulmonary function test is performed using a combination of ipratropium and salbutamol<span class="elsevierStyleSup">18</span>&#46; In effect&#44; although a few articles question the value of combination therapy with ipratropium bromide and a &#946;<span class="elsevierStyleInf">2</span>-AR agonist<span class="elsevierStyleSup">19&#44;20</span>&#44; several large trials suggest that the two drugs&#44; both at low doses<span class="elsevierStyleSup">21</span> and at high doses<span class="elsevierStyleSup">22&#44;23</span>&#44; have complementary&#44; or additive&#44; bronchodilator actions without any increase in the incidence of adverse reactions&#44; which makes them an excellent combination for the treatment of COPD&#46; The inclusion of a second agent of a different class in a pharmacologic treatment regimen is associated with a lower rate of exacerbations in COPD<span class="elsevierStyleSup">24</span>&#46; The overall result is lower total treatment costs and improved cost-effectiveness&#46;</p><p class="elsevierStylePara">The introduction of long acting &#946;<span class="elsevierStyleInf">2</span>-AR agonist bronchodilators gives physicians additional therapeutic options for COPD&#46; Both salmeterol and formoterol appear to be more effective than short acting &#946;<span class="elsevierStyleInf">2</span>-AR agonists<span class="elsevierStyleSup">25</span> and in patients with stable COPD they are more effective than anticholinergic agents<span class="elsevierStyleSup">26-28</span>&#46;</p><p class="elsevierStylePara">Two published studies that had evaluated small cohorts suggested that there is no substantial additive effect when a long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonist is combined with ipratropium bromide given acutely at the clinically recommended dose &#40;40 &#956;g&#41; in patients with COPD<span class="elsevierStyleSup">29&#44;30</span>&#44; but it must be stressed that the dose of ipratropium bromide needed to produce near maximal bronchodilation is several times higher than the customary dosage<span class="elsevierStyleSup">31</span>&#46; In fact&#44; the results of some studies suggest that higher than normal doses of an anticholinergic drug must be used for further relief of bronchospasm in patients with COPD when a single conventional inhaled dose of formoterol<span class="elsevierStyleSup">32</span> or salmeterol<span class="elsevierStyleSup">33</span> is given first&#46;</p><p class="elsevierStylePara">In any case&#44; van Noord et al<span class="elsevierStyleSup">34</span> demonstrated that a 12-week treatment with salmeterol 50 &#956;g twice daily plus ipratropium bromide 40 &#956;g four times daily was more effective than salmeterol 50 &#956;g twice daily in improving forced expiratory volume in 1 second &#40;FEV<span class="elsevierStyleInf">1</span>&#41; and specific airway conductance&#46; This study was the first to point out that the association of a long acting &#946;<span class="elsevierStyleInf">2</span>-AR agonist and an anticholinergic agent is useful in the long term therapy of stable COPD&#46;</p><p class="elsevierStylePara"> Subsequently&#44; D&#39;Urzo et al<span class="elsevierStyleSup">35</span> not only confirmed this therapeutic possibility&#44; but even documented that the addition of formoterol &#40;12 &#956;g twice daily&#41; to ipratropium bromide &#40;40 &#956;g four times a day&#41; is more effective than the addition of salbutamol &#40;200 &#956;g four times a day&#41; in patients with COPD who required combined bronchodilator therapy&#46; This finding clearly indicates that long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonists may represent the most effective option for combination therapy with an antimuscarinic agent&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">The functional impact of combining long-acting bronchodilators</span></p><p class="elsevierStylePara"> Clinical studies show that tiotropium administered 18 &#956;g once daily improves lung function over its 24-h dosing interval&#44; as shown by FEV<span class="elsevierStyleInf">1</span>&#44; forced vital capacity &#40;FVC&#41;&#44; peak expiratory flow rate &#40;PEFR&#41; and measures of hyperinflation and provides superior spirometric improvements compared with ipratropium 40 &#956;g four times daily<span class="elsevierStyleSup">36</span>&#46; Considering this important finding&#44; in an elegant review in which the pharmacological actions of the long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonists and a long-acting muscarinic antagonist &#40;tiotropium bromide&#41; were summarized&#44; Tennant et al<span class="elsevierStyleSup">37</span> highlighted the need for investigating the combination of tiotropium bromide with a long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonist&#46; Afterwards&#44; Tashkin and Cooper<span class="elsevierStyleSup">38</span>&#44; using the traditional method of integrating research studies that&#44; unfortunately&#44; does not allow to determine if the differences between the study outcomes are due to chance&#44; to inadequate study methods or to systematic differences in the characteristics of the studies&#44; emphasized the advantage of tiotropium on long-acting &#946;<span class="elsevierStyleInf">2</span>-agonists&#44; and suggested adding salmeterol or formoterol to tiotropium bromide&#44; at least in patients suffering from COPD with more severe symptoms &#40;stage III or IV of the GOLD classification<span class="elsevierStyleSup">1</span>&#46; However&#44; Cazzola and Matera<span class="elsevierStyleSup">39</span> in an accompanying editorial comment highlighted that no published study has documented the superiority of tiotropium over formoterol&#44; although two studies&#44; specifically designed to explore the potential differences between tiotropium and salmeterol&#44; seem to indicate a greater efficacy of tiotropium than long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonists<span class="elsevierStyleSup">40&#44;41</span>&#46; The different pharmacodynamic profile of formoterol when compared to salmeterol<span class="elsevierStyleSup">25</span> might induce a different type of broncholytic effect&#44; mainly if one considers onset of action or peak bronchodilation&#46; This may lead to a different conclusion when comparing formoterol with salmeterol&#46; Moreover&#44; it is not known if the combination of a long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonist and a long-acting antimuscarinic agent provides further advantages in terms of bronchodilation over either drug alone&#44; nor if the choice of the specific long-acting &#946;<span class="elsevierStyleInf">2</span>-agonist to be used is trivial&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleItalic">Acute functional effect of combining formoterol or salmeterol and tiotropium</span></p><p class="elsevierStylePara"> Some studies have tried to give an answer to these questions&#46; A pilot investigational trial<span class="elsevierStyleSup">42</span>&#44; which enrolled 20 outpatients clinically diagnosed with stable COPD and a mean baseline FEV<span class="elsevierStyleInf">1</span> of 0&#46;87 l &#40;95&#37; confidence interval &#91;CI&#93;&#44; 0&#46;70-1&#46;04&#41; and FVC of 1&#46;49 l &#40;95&#37; CI&#44; 1&#46;30-1&#46;69&#41;&#44; showed that 12 &#956;g formoterol&#44; either alone or in combination with 18 &#956;g tiotropium&#44; elicited a significantly faster onset of action &#40;the change in FEV<span class="elsevierStyleInf">1</span> 10 min after inhalation of formoterol alone &#91;0&#46;088 l&#59; 95&#37; CI&#44; 0&#46;049-0&#46;127&#93; was greater than that induced by tiotropium alone &#91;0&#46;039 l&#59; 95&#37; CI&#44; 0&#46;006-0&#46;071&#93;&#44; but not than that elicited by formoterol &#43; tiotropium &#91;0&#46;085 l&#59; 95&#37; CI&#44; 0&#46;044-0&#46;126&#93;&#41; &#40;fig&#46; 2 A&#41;&#46; Moreover&#44; this study also documented a trend for a greater maximum bronchodilation with combination than with formoterol or tiotropium alone &#40;the mean maximum increases in FEV<span class="elsevierStyleInf">1</span> from pre-dosing value on each of the dosing days were 0&#46;192 l &#91;95&#37; CI&#44; 0&#46;125-0&#46;259&#93; for formoterol&#44; 0&#46;176 l &#91;95&#37; CI&#44; 0&#46;100-0&#46;253&#93; for tiotropium&#44; and 0&#46;210 l &#40;95&#37; CI&#44; 0&#46;158-0&#46;261&#93; for the combination and occurred two hours after formoterol and three hours after inhalation of tiotropium and the combination&#44; but the difference between treatments was not significant &#91;p &#61; 0&#46;475&#93;&#41; &#40;fig&#46; 2 B&#41;&#46; At twenty four hours&#44; mean FEV<span class="elsevierStyleInf">1</span> continued to be significantly higher than pre-dosing value following tiotropium &#40;0&#46;084 l&#59; 95&#37; CI&#44; 0&#46;003-0&#46;134&#59; p &#61; 0&#46;003&#41; and formoterol &#43; tiotropium 0&#46;088 l&#59; 95&#37; CI&#44; 0&#46;002-0&#46;173&#59; p &#61; 0&#46;045&#41;&#44; but did not achieve significance for formoterol alone &#40;0&#46;058 l&#59; 95&#37; CI&#44; 0&#46;000-0&#46;117&#59; p &#61; 0&#46;051&#41; &#40;fig&#46; 2 B&#41;&#46; However&#44; at this time point&#44; the differences between treatments were not significant &#40;p &#61; 0&#46;731&#41;&#46; The failure to show a statistically significant difference between treatments when we explored the maximum bronchodilation and the duration of action was likely associated with an insufficient statistical power in the study&#46; We believe that there was a possibility of a type II error&#44; which supported the lack of significance that we have repeatedly observed&#46; It is possible that a study with a larger sample would achieve statistical significance&#46;</p><p class="elsevierStylePara"><img src="6v41nSupl.2-13084073tab02.gif"></img></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Fig&#46; 2&#46; Mean changes &#40;&#177; SE&#41; in FEV<span class="elsevierStyleInf">1</span> &#40;l&#41; from pre-dosing value on each of the dosing days up to 90 min &#40;A&#41; and up to 24 h &#40;B&#41; after inhalation of formoterol 12</span> &#956;<span class="elsevierStyleBold">g &#40;FOR&#41;&#44; tiotropium 18</span> &#956;<span class="elsevierStyleBold">g &#40;TIO&#41;&#44; and tiotropium 18</span> &#956;<span class="elsevierStyleBold">g &#43; formoterol 12</span> &#956;<span class="elsevierStyleBold">g &#40;TIO &#43; FOR&#41;&#46; <span class="elsevierStyleSup">&#42;</span>p &#60; 0&#46;05&#59; <span class="elsevierStyleSup">&#42;&#42;</span>p &#60; 0&#46;01&#59; <span class="elsevierStyleSup">&#42;&#42;&#42;</span>p &#60; 0&#46;001 versus baseline&#46; &#40;Data from Cazzola et al<span class="elsevierStyleSup">42</span>&#46;&#41;</span></p><p class="elsevierStylePara">The results of this study indicate that formoterol and tiotropium have different profiles &#40;formoterol has a faster onset of action and greater bronchodilating effect&#44; tiotropium has a longer duration of action&#44; which allows for once daily administration&#41; that make both agents attractive alternatives in the treatment of stable COPD&#46; Moreover&#44; the two drugs appear complementary&#58; tiotropium ensures prolonged bronchodilation&#44; whereas formoterol adds fast onset and a greater peak effect&#46; However&#44; because formoterol is given twice daily&#44; but tiotropium is required only once daily&#44; and results of our study do not allow suggesting the once daily dosing of formoterol&#44; the challenge is to develop a combined inhaler that can be employed on a daily basis<span class="elsevierStyleSup">37</span>&#46; The pharmacodynamic characteristics of salmeterol might permit the once daily contemporaneous administration of the two drugs that could simplify the therapy<span class="elsevierStyleSup">39</span>&#46;</p><p class="elsevierStylePara">In a further study<span class="elsevierStyleSup">43</span> that has enrolled 20 outpatients with stable COPD and a mean baseline FEV<span class="elsevierStyleInf">1</span> of 1&#46;10 l &#40;95&#37; CI&#44; 0&#46;91-1&#46;29&#41; and FVC of 1&#46;85 l &#40;95&#37; CI&#44; 1&#46;62-2&#46;07&#41;&#44; single doses of 18 &#956;g tiotropium&#44; 50 &#956;g salmeterol&#44; and 18 &#956;g tiotropium &#43; 50-&#956;g salmeterol were given&#46; The change in FEV<span class="elsevierStyleInf">1</span> 30 min after inhalation of salmeterol alone &#40;0&#46;058 l&#59; 95&#37; CI&#44; 0&#46;032-0&#46;083&#41; was greater than that induced by tiotropium alone &#40;0&#46;037 l&#59; 95&#37; CI&#44; 0&#46;013-0&#46;062&#41;&#44; but not than that elicited by tiotropium &#43; salmeterol &#40;0&#46;121 l&#59; 95&#37; CI&#44; 0&#46;073-0&#46;170&#41; &#40;fig&#46; 3 A&#41;&#46; The difference between the improvement after salmeterol and that after tiotropium was not statistically significant &#40;p &#61; 0&#46;231&#41;&#44; but the differences between the improvement after tiotropium &#43; salmeterol and that after tiotropium alone and salmeterol alone were statistically significant &#40;p &#61; 0&#46;014 and p &#61; 0&#46;026&#44; respectively&#41;&#46; The mean maximum increases in FEV<span class="elsevierStyleInf">1</span> from pre-dosing value on each of the dosing days were 0&#46;165 l &#40;95&#37; CI&#44; 0&#46;098-0&#46;232&#41; for tiotropium&#44; 0&#46;241 l &#40;95&#37; CI&#44; 0&#46;151-0&#46;332&#41; for salmeterol&#44; and 0&#46;290 l &#40;95&#37; CI&#44; 0&#46;228-0&#46;353&#41; for the combination and occurred four hours after inhalation of tiotropium or salmeterol and three hours after that of the combination &#40;fig&#46; 3 B&#41;&#46; At twenty four hours&#44; the mean FEV<span class="elsevierStyleInf">1</span> value was still higher than the mean pre-dosing value for tiotropium &#40;0&#46;042 l&#59; 95&#37; CI&#44; &#173;0&#46;012 to 0&#46;097&#59; p &#61; 0&#46;119&#41; and the tiotropium &#43; salmeterol combination &#40;0&#46;051 l&#59; 95&#37; CI&#44; 0&#46;015-0&#46;087&#59; p &#61; 0&#46;008&#41;&#44; but not for salmeterol alone &#40;&#173;0&#46;013 l&#59; 95&#37; CI&#44; &#173;0&#46;041 to 0&#46;014&#59; p &#61; 0&#46;324&#41; &#40;fig&#46; 3 B&#41;&#46; At this time point&#44; the differences between tiotropium and salmeterol and between salmeterol and tiotropium &#43; salmeterol&#44; but not that between tiotropium and tiotropium &#43; salmeterol&#44; were statistically significant &#40;p &#61; 0&#46;010&#44; p &#61; 0&#46;006&#44; and p &#61; 0&#46;752&#44; respectively&#41;&#46;</p><p class="elsevierStylePara"><img src="6v41nSupl.2-13084073tab03.gif"></img></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Fig&#46; 3&#46; Mean changes &#40;&#177; SE&#41; in FEV<span class="elsevierStyleInf">1</span> &#40;l&#41; from pre-dosing value on each of the dosing days up to 90 min &#40;A&#41; and up to 24 h &#40;B&#41; after inhalation of salmeterol 50</span> &#956;<span class="elsevierStyleBold">g &#40;SALM&#41;&#44; tiotropium 18</span> &#956;<span class="elsevierStyleBold">g &#40;TIO&#41;&#44; and salmeterol 50</span> &#956;<span class="elsevierStyleBold">g &#43; tiotropium 18</span> &#956;<span class="elsevierStyleBold">g &#40;SALM &#43; TIO&#41;&#46; <span class="elsevierStyleSup"> &#42;</span>p &#60; 0&#46;05&#59; <span class="elsevierStyleSup">&#42;&#42;</span>p &#60; 0&#46;01&#59; <span class="elsevierStyleSup">&#42;&#42;&#42;</span>p &#60; 0&#46;001 versus baseline&#46; &#40;Data from Cazzola et al<span class="elsevierStyleSup">43</span>&#46;&#41;</span></p><p class="elsevierStylePara"> These findings support the possibility of combining tiotropium and salmeterol in patients suffering from stable COPD&#44; but exclude the once-daily co-administration of the two drugs&#46; The potential of salmeterol to increase its onset of action when combined with tiotropium is worthy of attention considering that both agents elicit a slow onset of action<span class="elsevierStyleSup">44&#44;45</span>&#46; Ethier et al<span class="elsevierStyleSup">46</span> documented that at the lowest concentration of salmeterol needed to maximally stimulate cAMP accumulation&#44; this long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonist antagonized muscarinic inhibition of cAMP accumulation and altered agonist binding to muscarinic receptors in bovine trachealis cells&#46; Because salmeterol altered agonist&#44; but not antagonist&#44; binding and appeared to have an effect on the proportion of high affinity binding sites&#44; Ethier et al<span class="elsevierStyleSup">46</span> speculated that salmeterol has a low affinity binding interaction with the muscarinic receptor&#47;G-protein complex itself or reversibly alters the plasma membrane environment surrounding the complex&#46; In any case&#44; these effects of salmeterol did not depend on stimulation of &#946;<span class="elsevierStyleInf">2</span>-ARs&#46; If this finding were also true for human airways&#44; we could speculate that salmeterol reduces the bronchospastic activity of endogenous ACh&#44; without influencing the effect of tiotropium&#46; Salmeterol has also high affinity for muscarinic receptors<span class="elsevierStyleSup">47</span> and this indicates a potential for amplifying the action of tiotropium&#46; However&#44; the question of whether high local concentrations after inhalation of salmeterol could contribute to its therapeutic effects by antagonism with ACh on muscarinic receptors remains to be answered<span class="elsevierStyleSup">47</span>&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleItalic">Functional effect of a regular treatment with formoterol or salmeterol and tiotropium</span></p><p class="elsevierStylePara"> Although these results indicate that a combination of tiotropium and a long-acting &#946;-AR agonist is more effective than single drugs alone in inducing bronchodilation in patients suffering from COPD&#44; there is a fundamental aspect of these studies&#44; the evaluation of the impact of the three treatments only after acute administration&#44; that must be taken into account&#46; Acute administration is&#44; in fact&#44; a potential bias because it is well known that FEV<span class="elsevierStyleInf">1</span> steady state with tiotropium is reached within forty eight hours&#44; while continued improvements in FVC can be expected over or beyond the first week of therapy<span class="elsevierStyleSup">48</span>&#46; The progressive increases in FVC beyond forty eight hours suggest that maintenance bronchodilator therapy is required to achieve maximal changes in hyperinflation&#46;</p><p class="elsevierStylePara"> Data of a trial<span class="elsevierStyleSup">49</span> that compared the lung function response of the free combination of 18 &#956;g tiotropium plus 12 &#956;g formoterol once daily with 18 &#956;g tiotropium once daily and 12 &#956;g formoterol twice daily&#44; with all treatments administered for 6-week periods&#44; in 66 patients with moderate-to-severe stable COPD&#44; documented that the free combination of once daily tiotropium plus formoterol was better than either of the single drugs for most of the spirometric endpoints&#46; Tiotropium once daily was superior to formoterol twice daily during the daytime&#46; However&#44; during the night-time&#44; tiotropium and formoterol provided similar bronchodilation&#46; In particular&#44; the average FEV<span class="elsevierStyleInf">1</span> area under the curve &#40;AUC&#41;<span class="elsevierStyleInf">0-24h</span> was 85 ml after tiotropium&#44; 62 ml after formoterol and 160 ml after tiotropium &#43; formoterol&#44; the average FEV<span class="elsevierStyleInf">1</span> AUC<span class="elsevierStyleInf">0-12h</span> was 127 ml after tiotropium&#44; 86 ml after formoterol and 234 ml after tiotropium &#43; formoterol&#44; whereas the average FEV<span class="elsevierStyleInf">1</span> AUC<span class="elsevierStyleInf">12-24h</span> was 43 ml after tiotropium&#44; 38 ml after formoterol and 86 ml after tiotropium &#43; formoterol &#40;fig&#46; 4&#41;&#46; All FEV<span class="elsevierStyleInf">1</span> AUC after tiotropium &#43; formoterol were significantly &#40;p &#60; 0&#46;05&#41; larger than that of tiotropium or formoterol alone&#46; The daytime&#44; but not the night-time&#44; use of rescue salbutamol was significantly reduced in patients receiving the combination of tiotropium &#43; formoterol &#40;p &#60; 0&#46;05 versus either drug alone&#41;&#46; The documentation that tiotropium was more active than formoterol in daytime but not in night-time was&#44; in our opinion&#44; in agreement with the fact that the activity in the sympathetic system appears to be prominent during the day as reflected by the peak located around noon of the urinary catecholamine excretion&#44; whereas the vagal system appears to be prominent during the remainder of the day<span class="elsevierStyleSup">50</span>&#46; In any case&#44; these results indicate that once daily combination therapy of tiotropium &#43; formoterol is safe and provides significant additive effects in patients with moderate-to-severe COPD&#46; Moreover&#44; they suggest that once daily administration of the two drugs could be a possibility in the treatment of stable COPD&#46; A bronchodilator-mediated symptom benefit of the once daily combination is also reflected in significant decrease in salbutamol use as rescue therapy&#46;</p><p class="elsevierStylePara"><img src="6v41nSupl.2-13084073tab04.gif"></img></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Fig&#46; 4&#46; Tiotropium 18</span> &#956;<span class="elsevierStyleBold">g once daily &#40;TIO qd&#41;&#44; tiotropium 18</span> &#956;<span class="elsevierStyleBold">g once daily &#43; add-on formoterol 12</span> &#956;<span class="elsevierStyleBold">g once daily &#40;TIO &#43; FORM qd&#41; and tiotropium 18</span> &#956;<span class="elsevierStyleBold">g once daily &#43; add-on formoterol 12</span> &#956;<span class="elsevierStyleBold">g twice daily &#40;TIO &#43; FORM bid&#41; FEV<span class="elsevierStyleInf">1</span> AUCs calculated using the trapezoidal rule divided by the corresponding observation time to report in ml units&#46; <span class="elsevierStyleSup">a</span>p &#60; 0&#46;05 versus formoterol&#59; <span class="elsevierStyleSup">b</span>p &#60; 0&#46;05 versus tiotropium&#46; &#40;Data from van Noord et al<span class="elsevierStyleSup">49</span>&#46;&#41;</span></p><p class="elsevierStylePara"> However&#44; another trial that explored tiotropium maintenance therapy in 91 patients with COPD and the twenty four hour spirometric benefit of adding once or twice daily formoterol during two-week treatment periods<span class="elsevierStyleSup">51</span>&#44; documented that add-on therapy of a second formoterol dose significantly &#40;p &#60; 0&#46;05&#41; improved FEV<span class="elsevierStyleInf">1</span> and FVC variables when compared with tiotropium &#43; formoterol once daily&#44; although most of the spirometric add-on benefit was found with the morning formoterol dose&#46; The average FEV<span class="elsevierStyleInf">1</span> AUC<span class="elsevierStyleInf">0-24h</span> was 80 ml after tiotropium&#44; 162 ml after tiotropium &#43; formoterol once daily and 198 ml after tiotropium &#43; formoterol twice daily&#44; the average FEV<span class="elsevierStyleInf">1</span> AUC<span class="elsevierStyleInf">0-12h</span> was 125 ml after tiotropium&#44; 238 ml after tiotropium &#43; formoterol once daily and 241 ml after tiotropium &#43; formoterol twice daily&#44; whereas the average FEV<span class="elsevierStyleInf">1</span> AUC<span class="elsevierStyleInf">12-24h</span> was 37 ml after tiotropium&#44; 89 ml after tiotropium &#43; formoterol once daily and 156 ml after tiotropium &#43; formoterol twice daily &#40;fig&#46; 5&#41;&#46; FEV<span class="elsevierStyleInf">1</span> AUC<span class="elsevierStyleInf">12-24h</span> of tiotropium &#43; formoterol twice daily value was significantly &#40;p &#60; 0&#46;05&#41; different from that of tiotropium &#43; formoterol once daily&#46; Inspiratory capacity &#40;IC&#41;&#44; which is an index of hyperinflation&#44; showed a circadian rhythm during both the baseline and the treatment periods&#46; The improvements in IC with both tiotropium alone and when combined with formoterol paralleled those in FVC&#46; Use of salbutamol as rescue therapy was comparable during add-on therapy of formoterol once daily and formoterol twice daily&#46;</p><p class="elsevierStylePara"><img src="6v41nSupl.2-13084073tab05.gif"></img></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Fig&#46; 5&#46; Tiotropium 18</span> &#956;<span class="elsevierStyleBold">g once daily &#40;TIO qd&#41;&#44; formoterol 12</span> &#956;<span class="elsevierStyleBold">g twice daily &#40;FORM bid&#41; and tiotropium 18</span> &#956;<span class="elsevierStyleBold">g &#43; formoterol 12</span> &#956;<span class="elsevierStyleBold">g once daily &#40;TIO &#43; FORM qd&#41; FEV<span class="elsevierStyleInf">1</span> AUCs calculated using the trapezoidal rule divided by the corresponding observation time to report in ml units&#46; <span class="elsevierStyleSup"> a</span>p &#60; 0&#46;05 versus formoterol&#59; <span class="elsevierStyleSup">b</span>p &#60; 0&#46;05 versus tiotropium&#46; &#40;Data from van Noord et al<span class="elsevierStyleSup">51</span>&#46;&#41;</span></p><p class="elsevierStylePara"><span class="elsevierStyleItalic">The best strategy for adding long-acting</span> &#946;<span class="elsevierStyleItalic"><span class="elsevierStyleInf">2</span>-agonists and long-acting anticholinergics</span></p><p class="elsevierStylePara"> These findings raise an important question&#46; What is the best strategy for adding long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonists and long-acting anticholinergics in COPD&#63; Some studies have examined various strategies for adding short-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonists and anticholinergics in COPD&#46; Unfortunately&#44; they have provided conflicting results&#46; Rennard<span class="elsevierStyleSup">52</span> has correctly stressed that this may depend on the nature of the circumstances of the patient at the time when the study was carried out and may depend on the design by which the studies were conducted and the drugs administered&#46;</p><p class="elsevierStylePara">In one of our previous trials&#44; which was the first to our knowledge that compared a long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonist and an anticholinergic agent given by sequential inhalation at the recommended dosages&#44; we documented that the sequential administration of formoterol and oxitropium bromide induced an improvement in pulmonary function in a population of COPD patients similar to that examined in the present trial<span class="elsevierStyleSup">53</span>&#46; However&#44; prior administration of the long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonist allowed a response to the anticholinergic drug&#44; which was higher than that observed when inhalation of oxitropium was preceded by that of formoterol&#46;</p><p class="elsevierStylePara">In order to explore whether this finding is true even when tiotropium is used instead of oxitropium&#44; we have examined the potential of an additive effect of a recommended dose of second long-acting bronchodilator &#40;tiotropium or formoterol&#41; in COPD patients under regular treatment with a long-acting bronchodilator of a different class &#40;formoterol or tiotropium&#44; respectively&#41;&#46; We conducted a randomized&#44; crossover trial in 20 patients with 18 &#956;g tiotropium once daily and 12 &#956;g formoterol twice daily over a five-day period for each drug&#44; with a ten-day washout period<span class="elsevierStyleSup">54</span>&#46; At the end of each period&#44; patients inhaled both drugs separated by 180 min in alternate sequence&#46; Thirty minutes after inhalation of the last dose of tiotropium&#44; there was a statistically significant increase of 0&#46;099 l &#40;95&#37; CI&#44; 0&#46;062-0&#46;138&#41; in FEV<span class="elsevierStyleInf">1</span> over baseline &#40;p &#60; 0&#46;0001&#41; &#40;fig&#46; 6&#41;&#46; The same was observed after inhalation of the last dose of formoterol &#40;0&#46;166 l&#59; 95&#37; CI&#44; 0&#46;064-0&#46;168&#59; p &#60; 0&#46;0002&#41;&#46; The mean maximal change in FEV<span class="elsevierStyleInf">1</span> over baseline was 0&#46;226 l &#40;0&#46;154-0&#46;298&#41; in group A &#40;regular tiotropium and add-on formoterol&#41; and 0&#46;228 l &#40;0&#46;165-0&#46;291&#41; in group B &#40;regular formoterol and add-on tiotropium&#41;&#46; The mean maximal change in FEV<span class="elsevierStyleInf">1</span> over pre-inhalation of the second drug value was 0&#46;081 l &#40;95&#37; CI&#44; 0&#46;029-0&#46;133&#41; after tiotropium &#8594; formoterol and 0&#46;054 l &#40;95&#37; CI&#44; 0&#46;016-0&#46;092&#41; after formoterol &#8594; tiotropium&#46; The mean maximal change in FVC over baseline was 0&#46;519 l &#40;95&#37; CI&#44; 0&#46;361-0&#46;676&#41; in group A and 0&#46;495 l &#40;95&#37; CI&#44; 0&#46;307-0&#46;683&#41; in group B&#46; The mean maximal change in FVC over pre-inhalation of the second drug value was 0&#46;159 l &#40;95&#37; CI&#44; 0&#46;048-0&#46;270&#41; after tiotropium-formoterol and 0&#46;175 l &#40;95&#37; CI&#44; 0&#46;083-0&#46;266&#41; after formoterol &#8594; tiotropium&#46;</p><p class="elsevierStylePara"><img src="6v41nSupl.2-13084073tab06.gif"></img></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Fig&#46; 6&#46; Mean response curves following the sequential inhalation of tiotropium &#40;Tio&#41; and formoterol &#40;For&#41; for FEV<span class="elsevierStyleInf">1</span> and FVC&#46; Arrow indicates the administration of the second drug&#46; <span class="elsevierStyleSup">&#42;</span>p &#60; 0&#46;05&#59; <span class="elsevierStyleSup">&#42;&#42;</span>p &#60; 0&#46;01&#59; <span class="elsevierStyleSup">&#42;&#42;&#42;</span>p &#60; 0&#46;001 in the sequence tiotropium</span> &#8594; <span class="elsevierStyleBold">formoterol&#46; <span class="elsevierStyleSup">&#167;</span>p &#60; 0&#46;05&#59; <span class="elsevierStyleSup"> &#167;&#167;</span>p &#60; 0&#46;01&#59; <span class="elsevierStyleSup">&#167;&#167;&#167;</span>p &#60; 0&#46;001 in the sequence formoterol</span> &#8594; <span class="elsevierStyleBold">tiotropium&#46; &#40;Data from Cazzola et al<span class="elsevierStyleSup">54</span>&#46;&#41;</span></p><p class="elsevierStylePara"> These results suggest that supplementing a second different long-acting bronchodilator to a regularly administered long-acting bronchodilator seems to be to the patient&#39;s advantage in terms of bronchodilation&#46; We cannot exclude that the greater bronchodilatory response that we observed when a second bronchodilator was given after the first one may be justified by a carry over effect&#44; considering that both formoterol and tiotropium are long-lasting bronchodilators&#46; Nonetheless&#44; it is well know that the mean peak bronchodilation with both formoterol and tiotropium in COPD patients is reached after two to three hours<span class="elsevierStyleSup">43</span> and we have documented that the addition of a second bronchodilator three hours after the inhalation of the first agent&#44; could amplify the maximum bronchodilation of the first agent&#46; This result seems to be important because it indicates the possibility that a patient who is unable to perceive bronchodilation or must perform an exercise could use a second long-acting bronchodilator that will assure a long-lasting effect&#46; In any case&#44; it must be highlighted that significant improvement in pulmonary function has been achieved by adding tiotropium or formoterol at the recommended dosages in patients already in regular treatment with formoterol or tiotropium&#44; respectively&#44; with no statistically significant difference between the different sequences&#46; This finding supports Rennard&#39;s opinion<span class="elsevierStyleSup">3</span> that treatment can be initiated with an agent from any of the available classes&#46; If symptomatic control is inadequate&#44; an agent from another class can be added&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold"> Conclusions</span></p><p class="elsevierStylePara">At present time&#44; there is no clear documentation that tiotropium is superior to formoterol or the contrary&#46; At the recommend doses for COPD therapy&#44; formoterol twice daily and tiotropium once daily induce comparable night time bronchodilation after regular treatment<span class="elsevierStyleSup">49</span>&#46;</p><p class="elsevierStylePara">A combination of tiotropium and a long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonist is more effective than single drugs alone in inducing bronchodilation and bronchodilator-mediated symptom benefit in patients suffering from COPD<span class="elsevierStyleSup">42&#44;43&#44;49&#44;51</span>&#46; Add-on therapy of formoterol in the morning to maintenance therapy with tiotropium significantly improves FEV<span class="elsevierStyleInf">1</span> and IC for more than twelve hours in patients with moderate-to-severe COPD<span class="elsevierStyleSup">51</span>&#46; Add-on therapy of a second formoterol dose administered in the evening produces a further increase in average FEV<span class="elsevierStyleInf">1</span> and IC&#44; but not in trough IC<span class="elsevierStyleSup">51</span>&#46; All these findings support&#44; in our opinion&#44; the possibility of combining tiotropium and formoterol&#44; and likely salmeterol&#44; in patients suffering from stable COPD&#44; but exclude the once-daily administration of the two drugs in combination within a single inhaler&#46; It must be determined yet whether tiotropium is more effective when administered in the evening compared with morning dosing&#44; in view of the circadian variation of bronchial tone&#46;</p><p class="elsevierStylePara"> Because long-acting &#946;<span class="elsevierStyleInf">2</span>-AR agonists are given twice daily but tiotropium bromide is required only once daily&#44; the challenge is now to develop a combined inhaler that can be employed on a once daily basis&#46; The incorporation of once daily dosing is an important strategy to improve compliance since it is a regime preferred by most patients&#46;</p><hr></hr><p class="elsevierStylePara"> Correspondencia&#58; M&#46; Cazzola&#46;<br></br> Via del Parco Margherita&#44; 24&#46; 80121 Napoli&#46; Italy&#46;<br></br> E-mail&#58; <a href="mailto&#58;mcazzola&#64;qubisoft&#46;it" class="elsevierStyleCrossRefs"> mcazzola&#64;qubisoft&#46;it</a></p>"
    "pdfFichero" => "6v41nSupl.2a13084073pdf001.pdf"
    "tienePdf" => true
    "multimedia" => array:12 [
      0 => array:8 [
        "identificador" => "tbl1"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "6v41nSupl.2-13084073tab01.gif"
                  "imagenAlto" => 936
                  "imagenAncho" => 1086
                  "imagenTamanyo" => 60712
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Schematic presentation of the potential alternative role of &#946;2-adrenoceptor &#40;AR&#41; in the pre-synaptic control of acetylcholine &#40;ACh&#41; release from airway parasympathetic nerve endings&#46; A&#58; circulating adrenaline&#59; &#946;2-AR&#58; &#946;2-adrenoceptor&#59; M1 and M3&#58; muscarinic M1 or M3 receptors&#59; &#40;&#62;&#58; neuronal activity&#59; &#8594;&#58; stimulatory effect&#59; &#40;&#61;&#8595;&#58; inhibitory effect&#46;"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl2"
        "etiqueta" => "Fig. 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "6v41nSupl.2-13084073tab02.gif"
                  "imagenAlto" => 1532
                  "imagenAncho" => 1083
                  "imagenTamanyo" => 50576
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Mean changes &#40;&#177; SE&#41; in FEV1 &#40;l&#41; from pre-dosing value on each of the dosing days up to 90 min &#40;A&#41; and up to 24 h &#40;B&#41; after inhalation of formoterol 12 &#956;g &#40;FOR&#41;&#44; tiotropium 18 &#956;g &#40;TIO&#41;&#44; and tiotropium 18 &#956;g &#43; formoterol 12 &#956;g &#40;TIO &#43; FOR&#41;&#46; &#42;p &#60; 0&#46;05&#59; &#42;&#42;p &#60; 0&#46;01&#59; &#42;&#42;&#42;p &#60; 0&#46;001 versus baseline&#46; &#40;Data from Cazzola et al42&#46;&#41;"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl3"
        "etiqueta" => "Fig. 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "6v41nSupl.2-13084073tab03.gif"
                  "imagenAlto" => 1535
                  "imagenAncho" => 1083
                  "imagenTamanyo" => 52741
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Mean changes &#40;&#177; SE&#41; in FEV1 &#40;l&#41; from pre-dosing value on each of the dosing days up to 90 min &#40;A&#41; and up to 24 h &#40;B&#41; after inhalation of salmeterol 50 &#956;g &#40;SALM&#41;&#44; tiotropium 18 &#956;g &#40;TIO&#41;&#44; and salmeterol 50 &#956;g &#43; tiotropium 18 &#956;g &#40;SALM &#43; TIO&#41;&#46; &#42;p &#60; 0&#46;05&#59; &#42;&#42;p &#60; 0&#46;01&#59; &#42;&#42;&#42;p &#60; 0&#46;001 versus baseline&#46; &#40;Data from Cazzola et al43&#46;&#41;"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl4"
        "etiqueta" => "Fig. 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "6v41nSupl.2-13084073tab04.gif"
                  "imagenAlto" => 891
                  "imagenAncho" => 1083
                  "imagenTamanyo" => 25691
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Tiotropium 18 &#956;g once daily &#40;TIO qd&#41;&#44; tiotropium 18 &#956;g once daily &#43; add-on formoterol 12 &#956;g once daily &#40;TIO &#43; FORM qd&#41; and tiotropium 18 &#956;g once daily &#43; add-on formoterol 12 &#956;g twice daily &#40;TIO &#43; FORM bid&#41; FEV1 AUCs calculated using the trapezoidal rule divided by the corresponding observation time to report in ml units&#46; ap &#60; 0&#46;05 versus formoterol&#59; bp &#60; 0&#46;05 versus tiotropium&#46; &#40;Data from van Noord et al49&#46;&#41;"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl5"
        "etiqueta" => "Fig. 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "6v41nSupl.2-13084073tab05.gif"
                  "imagenAlto" => 889
                  "imagenAncho" => 1079
                  "imagenTamanyo" => 26911
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Tiotropium 18 &#956;g once daily &#40;TIO qd&#41;&#44; formoterol 12 &#956;g twice daily &#40;FORM bid&#41; and tiotropium 18 &#956;g &#43; formoterol 12 &#956;g once daily &#40;TIO &#43; FORM qd&#41; FEV1 AUCs calculated using the trapezoidal rule divided by the corresponding observation time to report in ml units&#46; ap &#60; 0&#46;05 versus formoterol&#59; bp &#60; 0&#46;05 versus tiotropium&#46; &#40;Data from van Noord et al51&#46;&#41;"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl6"
        "etiqueta" => "Fig. 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "6v41nSupl.2-13084073tab06.gif"
                  "imagenAlto" => 1514
                  "imagenAncho" => 1091
                  "imagenTamanyo" => 42534
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Mean response curves following the sequential inhalation of tiotropium &#40;Tio&#41; and formoterol &#40;For&#41; for FEV1 and FVC&#46; Arrow indicates the administration of the second drug&#46; &#42;p &#60; 0&#46;05&#59; &#42;&#42;p &#60; 0&#46;01&#59; &#42;&#42;&#42;p &#60; 0&#46;001 in the sequence tiotropium &#8594; formoterol&#46; &#167;p &#60; 0&#46;05&#59; &#167;&#167;p &#60; 0&#46;01&#59; &#167;&#167;&#167;p &#60; 0&#46;001 in the sequence formoterol &#8594; tiotropium&#46; &#40;Data from Cazzola et al54&#46;&#41;"
        ]
      ]
      6 => array:5 [
        "identificador" => "tbl7"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
      7 => array:5 [
        "identificador" => "tbl8"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
      8 => array:5 [
        "identificador" => "tbl9"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
      9 => array:5 [
        "identificador" => "tbl10"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
      10 => array:5 [
        "identificador" => "tbl11"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
      11 => array:5 [
        "identificador" => "tbl12"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:54 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "referenciaCompleta" => "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2003 [accessed Dec 23, 2004]. Available at: http://www.goldcopd.com"
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Global Strategy for the Diagnosis&#44; Management&#44; and Prevention of Chronic Obstructive Pulmonary Disease&#44; 2003 &#91;accessed Dec 23&#44; 2004&#93;&#46; Available at&#58; http&#58;&#47;&#47;www&#46;goldcopd&#46;com"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Global Initiative for Chronic Obstructive Lung Disease&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "referenciaCompleta" => "Standards for the diagnosis and management of patients with COPD [accessed Dec 23, 2004]. Available at: http://www.thoracic.org"
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Standards for the diagnosis and management of patients with COPD &#91;accessed Dec 23&#44; 2004&#93;&#46; Available at&#58; http&#58;&#47;&#47;www&#46;thoracic&#46;org"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "American Thoracic Society&#47;European Respiratory Society&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Treatment of stable chronic obstructive pulmonary disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Rennard SI&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(04)16941-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2004"
                        "volumen" => "364"
                        "paginaInicial" => "791"
                        "paginaFinal" => "802"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15337408"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "referenciaCompleta" => "The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004;117 Suppl 1:24-32."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The role of anticholinergics in chronic obstructive pulmonary disease&#46; Am J Med&#46; 2004&#59;117 Suppl 1&#58;24-32&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Barnes PJ&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Neural regulation of airway smooth muscle tone&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Canning BJ"
                            1 => "Fischer A&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Respir Physiol"
                        "fecha" => "2001"
                        "volumen" => "125"
                        "paginaInicial" => "113"
                        "paginaFinal" => "27"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11240156"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Effective site of bronchodilation by &#946;-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease&#58; direct measurement of intrabronchial pressure with a new catheter&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Ohrui T"
                            1 => "Yanai M"
                            2 => "Sekiwzawa K"
                            3 => "Morikawa M"
                            4 => "Sasaki H"
                            5 => "Takishima T&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/ajrccm/146.1.88"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am Rev Respir Dis"
                        "fecha" => "1992"
                        "volumen" => "146"
                        "paginaInicial" => "88"
                        "paginaFinal" => "91"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1626821"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Ultrastructural studies on the neuromuscular control of human tracheal and bronchial muscle&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Daniel EE"
                            1 => "Kannan M"
                            2 => "Davis C"
                            3 => "Posey-Daniel V&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Respir Physiol"
                        "fecha" => "1986"
                        "volumen" => "63"
                        "paginaInicial" => "109"
                        "paginaFinal" => "28"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3952384"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Inhibition of cholinergic neurotransmission in human airways by &#946;2-adrenoceptors&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "Rhoden KJ"
                            1 => "Meldrum LA"
                            2 => "Barnes PJ&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Appl Physiol"
                        "fecha" => "1988"
                        "volumen" => "65"
                        "paginaInicial" => "700"
                        "paginaFinal" => "5"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2844715"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "&#946;-adrenoceptors mediate inhibition of &#91;3H&#93;-acetylcholine release from the isolated rat and guinea-pig trachea&#58; role of the airway mucosa and prostaglandins&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Wessler I"
                            1 => "Reinheimer T"
                            2 => "Brunn G"
                            3 => "Anderson GP"
                            4 => "Maclagan J"
                            5 => "Rack&#233; K&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Pharmacol"
                        "fecha" => "1994"
                        "volumen" => "113"
                        "paginaInicial" => "1221"
                        "paginaFinal" => "30"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7889276"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "&#946;2-Adrenoceptor activation augments acetylcholine release from tracheal parasympathetic nerves&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "Zhang XY"
                            1 => "Olszewski MA"
                            2 => "Robinson NE&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Physiol"
                        "fecha" => "1995"
                        "volumen" => "268"
                        "paginaInicial" => "L950"
                        "paginaFinal" => "6"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7611436"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenaline&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Belvisi MG"
                            1 => "Patel HJ"
                            2 => "Takahashi T"
                            3 => "Barnes PJ"
                            4 => "Giembycz MA&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Pharmacol"
                        "fecha" => "1996"
                        "volumen" => "117"
                        "paginaInicial" => "1413"
                        "paginaFinal" => "20"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8730733"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Enhancement of endogenous acetylcholine and norepinephrine release by prejunctional &#946;2-adrenoceptors in human isolated bronchi &#91;abstract&#93;&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "De Haas JR&#46;A"
                            1 => "Terpstra JS"
                            2 => "Zaagsma J"
                            3 => "Roffel AF&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Am J Respir Crit Care Med"
                        "fecha" => "1998"
                        "volumen" => "157"
                        "paginaInicial" => "723A"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Effects of enantiomers of &#946;2-agonists on ACh release and smooth muscle contraction in the trachea&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Zhang XY"
                            1 => "Zhu FX"
                            2 => "Olszewski MA"
                            3 => "Robinson NE&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Am J Physiol"
                        "fecha" => "1998"
                        "volumen" => "274"
                        "paginaInicial" => "32L"
                        "paginaFinal" => "8L"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Facilitatory &#946;2-adrenoceptors on cholinergic and adrenergic nerve endings of the guinea pig trachea&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "De Haas JR"
                            1 => "Terpstra JS"
                            2 => "Van der Zwaag M"
                            3 => "Kockelbergh PG"
                            4 => "Roffel AF"
                            5 => "Zaagsma J&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Am J Physiol Lung Cell Mol Physiol"
                        "fecha" => "1999"
                        "volumen" => "276"
                        "paginaInicial" => "L420"
                        "paginaFinal" => "5"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "Kume H"
                            1 => "Graziano MP"
                            2 => "Kotlikoff MI&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Proc Natl Acad Sci USA"
                        "fecha" => "1992"
                        "volumen" => "89"
                        "paginaInicial" => "11051"
                        "paginaFinal" => "5"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1438313"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Inhibition of cholinergic neurotransmission in guinea pig trachea by NS1619&#44; a putative activator of large-conductance&#44; calcium-activated potassium channels&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Patel HJ"
                            1 => "Giembycz MA"
                            2 => "Keeling JE"
                            3 => "Barnes PJ"
                            4 => "Belvisi MG&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Pharmacol Exp Ther"
                        "fecha" => "1998"
                        "volumen" => "286"
                        "paginaInicial" => "952"
                        "paginaFinal" => "8"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9694955"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Modulation of cholinergic responsiveness through the &#946;-adrenoceptor signal transmission pathway in bovine trachealis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Brichetto L"
                            1 => "Song P"
                            2 => "Crimi E"
                            3 => "Rehder K"
                            4 => "Brusasco V&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1152/japplphysiol.00028.2003"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Appl Physiol"
                        "fecha" => "2003"
                        "volumen" => "95"
                        "paginaInicial" => "735"
                        "paginaFinal" => "41"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12730144"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Dorinsky PM"
                            1 => "Reisner C"
                            2 => "Ferguson GT"
                            3 => "Menjoge SS"
                            4 => "Serby CW"
                            5 => "Witek TJ Jr&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "1999"
                        "volumen" => "115"
                        "paginaInicial" => "966"
                        "paginaFinal" => "71"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10208193"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A comparison of the bronchodilating effects of a &#946;-adrenergic agent &#40;albuterol&#41; and an anticholinergic agent &#40;ipratropium bromide&#41;&#44; given by aerosol alone or in sequence&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Easton PA"
                            1 => "Jadue C"
                            2 => "Dhingra S"
                            3 => "Anthonisen NR&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJM198609183151205"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "1986"
                        "volumen" => "315"
                        "paginaInicial" => "735"
                        "paginaFinal" => "9"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2943994"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "LeDoux EJ"
                            1 => "Morris JF"
                            2 => "Temple WP"
                            3 => "Duncan C&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "1989"
                        "volumen" => "95"
                        "paginaInicial" => "1013"
                        "paginaFinal" => "6"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2523291"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "In chronic obstructive pulmonary disease&#44; a combination of ipratropium and albuterol is more effective than either agent alone&#46; An 85-day multicenter trial&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "COMBIVENT Inhalation Aerosol Study Group&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "1994"
                        "volumen" => "105"
                        "paginaInicial" => "1411"
                        "paginaFinal" => "9"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8181328"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Addition of anticholinergic solution prolongs bronchodilator effect of &#946;2 agonists in patients with chronic obstructive pulmonary disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => "Levin DC"
                            1 => "Little KS"
                            2 => "Laughlin KR"
                            3 => "Galbraith JM"
                            4 => "Gustman PM"
                            5 => "Murphy D"
                            6 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Med"
                        "fecha" => "1996"
                        "volumen" => "100"
                        "paginaInicial" => "40S"
                        "paginaFinal" => "8S"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8610716"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Routine nebulized ipratropium and albuterol together are better than either alone in COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "COMBIVENT Inhalation Solution Study Group&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "1997"
                        "volumen" => "112"
                        "paginaInicial" => "1514"
                        "paginaFinal" => "21"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9404747"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Friedman M"
                            1 => "Serby CW"
                            2 => "Menjoge SS"
                            3 => "Wilson JD"
                            4 => "Hilleman DE"
                            5 => "Witek TJ Jr&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "1999"
                        "volumen" => "115"
                        "paginaInicial" => "635"
                        "paginaFinal" => "41"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10084468"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => "Cazzola M"
                            1 => "Santangelo G"
                            2 => "Piccolo A"
                            3 => "Salzillo A"
                            4 => "Matera MG"
                            5 => "D&#39;Amato G"
                            6 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Pulm Pharmacol"
                        "fecha" => "1994"
                        "volumen" => "7"
                        "paginaInicial" => "103"
                        "paginaFinal" => "7"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7915921"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Efficacy of salmeterol xinafoate in the treatment of COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => "Mahler DA"
                            1 => "Donohue JF"
                            2 => "Barbee RA"
                            3 => "Goldman MD"
                            4 => "Gross NJ"
                            5 => "Wisniewski ME"
                            6 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "1999"
                        "volumen" => "115"
                        "paginaInicial" => "957"
                        "paginaFinal" => "65"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10208192"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Use of a long-acting inhaled &#946;2-adrenergic agonist&#44; salmeterol xinafoate&#44; in patients with chronic obstructive pulmonary disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => "Rennard SI"
                            1 => "Anderson W"
                            2 => "ZuWallack R"
                            3 => "Broughton J"
                            4 => "Bailey W"
                            5 => "Friedman M"
                            6 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/ajrccm.163.5.9903053"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med"
                        "fecha" => "2001"
                        "volumen" => "163"
                        "paginaInicial" => "1087"
                        "paginaFinal" => "92"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11316640"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => "Dahl R"
                            1 => "Greefhorst LA"
                            2 => "Nowak D"
                            3 => "Nonikov V"
                            4 => "Byrne AM"
                            5 => "Thomson MH"
                            6 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/ajrccm.164.5.2007006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med"
                        "fecha" => "2001"
                        "volumen" => "164"
                        "paginaInicial" => "778"
                        "paginaFinal" => "84"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11549532"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib29"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "Matera MG"
                            1 => "Caputi M"
                            2 => "Cazzola M&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Respir Med"
                        "fecha" => "1996"
                        "volumen" => "90"
                        "paginaInicial" => "497"
                        "paginaFinal" => "9"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8869445"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib30"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Bronchodilatory responses to formoterol&#44; ipratropium&#44; and their combination in patients with stable COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Sichletidis L"
                            1 => "Kottakis J"
                            2 => "Marcou S"
                            3 => "Constantinidis TC"
                            4 => "Antoniades A&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Clin Pract"
                        "fecha" => "1999"
                        "volumen" => "53"
                        "paginaInicial" => "185"
                        "paginaFinal" => "8"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10665129"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib31"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Ikeda A"
                            1 => "Nishimura K"
                            2 => "Koyama H"
                            3 => "Izumi T&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Thorax"
                        "fecha" => "1995"
                        "volumen" => "50"
                        "paginaInicial" => "62"
                        "paginaFinal" => "6"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7886652"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib32"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Cazzola M"
                            1 => "Matera MG"
                            2 => "Di Perna E"
                            3 => "Califano C"
                            4 => "D&#39;Amato M"
                            5 => "Mazzarella G&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Respir Med"
                        "fecha" => "1999"
                        "volumen" => "93"
                        "paginaInicial" => "909"
                        "paginaFinal" => "11"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10653054"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib33"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => "Cazzola M"
                            1 => "Di Perna F"
                            2 => "Centanni S"
                            3 => "Califano C"
                            4 => "Donner CF"
                            5 => "D&#39;Amato M"
                            6 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Thorax"
                        "fecha" => "1999"
                        "volumen" => "54"
                        "paginaInicial" => "1083"
                        "paginaFinal" => "6"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10567627"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib34"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Van Noord JA"
                            1 => "De Munck DR"
                            2 => "Bantje TA"
                            3 => "Hop WC"
                            4 => "Akveld ML"
                            5 => "Bommer AM&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir J"
                        "fecha" => "2000"
                        "volumen" => "15"
                        "paginaInicial" => "878"
                        "paginaFinal" => "85"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10853852"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib35"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "In patients with COPD&#44; treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium&#58; a 3-week&#44; randomized&#44; double-blind&#44; within-patient&#44; multicenter study&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => "D&#39;Urzo AD"
                            1 => "De Salvo MC"
                            2 => "Ram&#237;rez-Rivera A"
                            3 => "Almeida J"
                            4 => "Sichletidis L"
                            5 => "Rapatz G"
                            6 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "2001"
                        "volumen" => "119"
                        "paginaInicial" => "1347"
                        "paginaFinal" => "56"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11348938"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib36"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "referenciaCompleta" => "Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease. Am J Med. 2004;117 Suppl 1:33-40."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease&#46; Am J Med&#46; 2004&#59;117 Suppl 1&#58;33-40&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Casaburi R"
                            1 => "Conoscenti CS&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib37"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Tennant RC"
                            1 => "Erin EM"
                            2 => "Barnes PJ"
                            3 => "Hansel TT&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "-adrenoceptor agonists or tiotropium bromide for patients with COPD:is combination therapy justified? Curr Opin Pharmacol"
                        "fecha" => "2003"
                        "volumen" => "3"
                        "paginaInicial" => "270"
                        "paginaFinal" => "6"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12810191"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib38"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The role of long-acting bronchodilators in the management of stable COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Tashkin DP"
                            1 => "Cooper CB&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "2004"
                        "volumen" => "125"
                        "paginaInicial" => "249"
                        "paginaFinal" => "59"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14718448"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib39"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Long-acting bronchodilators are the first-choice option for the treatment of stable COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Cazzola M"
                            1 => "Matera MG&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "2004"
                        "volumen" => "125"
                        "paginaInicial" => "9"
                        "paginaFinal" => "11"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14718412"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib40"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A 6-month&#44; placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Donohue JF"
                            1 => "Van Noord JA"
                            2 => "Bateman ED"
                            3 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Chest"
                        "fecha" => "2002"
                        "volumen" => "122"
                        "paginaInicial" => "47"
                        "paginaFinal" => "55"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12114338"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib41"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Brusasco V"
                            1 => "Hodder R"
                            2 => "Miravitlles M"
                            3 => "Korducki L"
                            4 => "Towse L"
                            5 => "Kesten S&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Thorax"
                        "fecha" => "2003"
                        "volumen" => "58"
                        "paginaInicial" => "399"
                        "paginaFinal" => "404"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12728159"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib42"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The pharmacodynamic effects of single inhaled doses of formoterol&#44; tiotropium and their combination in patients with COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => "Cazzola M"
                            1 => "Di Marco F"
                            2 => "Santus P"
                            3 => "Boveri B"
                            4 => "Verga M"
                            5 => "Matera MG"
                            6 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Pulm Pharmacol Ther"
                        "fecha" => "2004"
                        "volumen" => "17"
                        "paginaInicial" => "35"
                        "paginaFinal" => "9"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14643169"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib43"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "The functional impact of adding salmeterol and tiotropium in patients with stable COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => "Cazzola M"
                            1 => "Centanni S"
                            2 => "Santus P"
                            3 => "Verga M"
                            4 => "Mondoni M"
                            5 => "Di Marco F"
                            6 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Respir Med"
                        "fecha" => "2004"
                        "volumen" => "98"
                        "paginaInicial" => "1214"
                        "paginaFinal" => "21"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15588043"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib44"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Effect of Ba 679 BR&#44; a novel long-acting anticholinergic agent&#44; on cholinergic neurotransmission in guinea pig and human airways&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => "Takahashi T"
                            1 => "Belvisi MG"
                            2 => "Patel H"
                            3 => "Ward JK"
                            4 => "Tadjkarimi S"
                            5 => "Yacoub MH"
                            6 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1164/ajrccm.150.6.7952627"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Respir Crit Care Med"
                        "fecha" => "1994"
                        "volumen" => "150"
                        "paginaInicial" => "1640"
                        "paginaFinal" => "5"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7952627"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib45"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "Anderson P"
                            1 => "Lotvall J"
                            2 => "Linden A&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Lung"
                        "fecha" => "1996"
                        "volumen" => "174"
                        "paginaInicial" => "159"
                        "paginaFinal" => "70"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8830192"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib46"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Effects of salmeterol on muscarinic inhibition of adenylyl cyclase in bovine trachealis cells&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Ethier MF"
                            1 => "Dextradeur T"
                            2 => "Schaefer OP"
                            3 => "Madison JM&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Life Sci"
                        "fecha" => "2000"
                        "volumen" => "67"
                        "paginaInicial" => "2753"
                        "paginaFinal" => "8"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11105991"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib47"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "Teschemacher A"
                            1 => "Reinhardt D"
                            2 => "Lemoine H&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "-sympathomimetics contribute to their relaxant effects in airway smooth muscle cells? Pulm Pharmacol Ther"
                        "fecha" => "1998"
                        "volumen" => "11"
                        "paginaInicial" => "253"
                        "paginaFinal" => "61"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib48"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Van Noord JA"
                            1 => "Smeets JJ"
                            2 => "Custers FL"
                            3 => "Korducki L"
                            4 => "Cornelissen PJ&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir J"
                        "fecha" => "2002"
                        "volumen" => "19"
                        "paginaInicial" => "639"
                        "paginaFinal" => "44"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11998992"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib49"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "referenciaCompleta" => "Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]. Am J Respir Crit Care Med. 2003;167 Suppl 7:320A."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Comparison of once daily tiotropium&#44; twice daily formoterol and the free combination&#44; once daily&#44; in patients with COPD &#91;abstract&#93;&#46; Am J Respir Crit Care Med&#46; 2003&#59;167 Suppl 7&#58;320A&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Van Noord JA"
                            1 => "Aumann J"
                            2 => "Janssens E"
                            3 => "Mueller A"
                            4 => "Cornelissen PJG&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib50"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Effects of two bronchodilatators&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "Gaultier C"
                            1 => "Reinberg A"
                            2 => "Girard E Circadian rhythms in lung resistance and dynamic lung compliance of healthy children&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Respir Physiol"
                        "fecha" => "1977"
                        "volumen" => "3l"
                        "paginaInicial" => "169"
                        "paginaFinal" => "82"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib51"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "referenciaCompleta" => "Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods [abstract]. Am J Respir Crit Care Med. 2003;167 Suppl 7:95A."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods &#91;abstract&#93;&#46; Am J Respir Crit Care Med&#46; 2003&#59;167 Suppl 7&#58;95A&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Van Noord JA"
                            1 => "Aumann J"
                            2 => "Janssens E"
                            3 => "Folgering H"
                            4 => "Mueller A"
                            5 => "Cornelissen PJG&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib52"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "referenciaCompleta" => "Combination bronchodilator therapy in COPD. Chest. 1995;107 Suppl:171-5."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Combination bronchodilator therapy in COPD&#46; Chest&#46; 1995&#59;107 Suppl&#58;171-5&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Rennard SI&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib53"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Cazzola M"
                            1 => "Di Perna F"
                            2 => "Califano C"
                            3 => "Vinciguerra A"
                            4 => "D&#39;Amato M&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1006/pupt.1999.0208"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pulm Pharmacol Ther"
                        "fecha" => "1999"
                        "volumen" => "12"
                        "paginaInicial" => "267"
                        "paginaFinal" => "71"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10501652"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib54"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "referenciaCompleta" => "Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med. In press 2005."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients&#46; Respir Med&#46; In press 2005&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Cazzola M"
                            1 => "Noschese P"
                            2 => "Salzillo A"
                            3 => "De Giglio C"
                            4 => "D&#39;Amato G"
                            5 => "Matera MG&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/03002896/00000041000000S2/v0_201307091044/13084073/v0_201307091045/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "14663"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Controversias en el tratamiento farmacol&#243;gico de la EPOC"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/03002896/00000041000000S2/v0_201307091044/13084073/v0_201307091045/en/6v41nSupl.2a13084073pdf001.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13084073?idApp=UINPBA00003Z"
]

Article information

ISSN: 03002896
Original language: English

DOI:10.1016/S0210-5705(09)71003-9

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	8	2	10
2024 October	64	27	91
2024 September	75	18	93
2024 August	81	38	119
2024 July	53	30	83
2024 June	80	25	105
2024 May	86	24	110
2024 April	62	20	82
2024 March	67	18	85
2024 February	62	30	92
2024 January	21	0	21
2023 December	8	0	8
2023 November	12	0	12
2023 October	15	6	21
2023 September	19	8	27
2023 August	29	14	43
2023 July	18	4	22
2023 June	16	0	16
2023 May	14	0	14
2023 April	12	0	12
2023 March	17	1	18
2023 February	12	20	32
2023 January	47	38	85
2022 December	67	41	108
2022 November	57	22	79
2022 October	60	65	125
2022 September	57	44	101
2022 August	53	40	93
2022 July	50	69	119
2022 June	48	44	92
2022 May	57	35	92
2022 April	60	33	93
2022 March	69	41	110
2022 February	43	34	77
2022 January	38	33	71
2021 December	24	25	49
2021 November	37	39	76
2021 October	42	40	82
2021 September	49	48	97
2021 August	26	43	69
2021 July	41	26	67
2021 June	53	26	79
2021 May	106	28	134
2021 April	223	62	285
2021 March	86	25	111
2021 February	70	10	80
2021 January	60	26	86
2020 December	62	15	77
2020 November	54	19	73
2020 October	43	20	63
2020 September	27	11	38
2020 August	45	15	60
2020 July	43	16	59
2020 June	49	10	59
2020 May	81	25	106
2020 April	40	19	59
2020 March	41	22	63
2020 February	44	24	68
2020 January	66	20	86
2019 December	59	23	82
2019 November	37	28	65
2019 October	29	14	43
2019 September	46	14	60
2019 August	27	12	39
2019 July	44	17	61
2019 June	42	17	59
2019 May	47	18	65
2019 April	38	35	73
2019 March	40	12	52
2019 February	55	12	67
2019 January	30	12	42
2018 December	45	18	63
2018 November	35	9	44
2018 October	73	15	88
2018 September	24	9	33
2018 July	1	0	1
2018 May	35	1	36
2018 April	32	9	41
2018 March	32	7	39
2018 February	45	13	58
2018 January	24	4	28
2017 December	39	10	49
2017 November	33	8	41
2017 October	27	6	33
2017 September	49	9	58
2017 August	62	9	71
2017 July	67	20	87
2017 June	82	17	99
2017 May	64	15	79
2017 April	74	7	81
2017 March	56	13	69
2017 February	31	6	37
2017 January	33	4	37
2016 December	56	15	71
2016 November	69	13	82
2016 October	86	28	114
2016 September	81	31	112
2016 August	26	19	45
2016 July	21	13	34
2016 June	25	23	48
2016 May	15	18	33
2016 April	17	2	19
2016 March	9	6	15
2016 February	32	4	36
2016 January	22	15	37
2015 December	33	32	65
2015 November	36	18	54
2015 October	124	6	130
2015 September	109	0	109
2015 August	78	0	78
2015 July	132	0	132
2015 June	71	0	71
2015 May	114	0	114
2015 April	78	0	78
2015 March	101	0	101
2015 February	108	0	108
2015 January	100	0	100
2014 December	116	0	116
2014 November	127	0	127
2014 October	169	0	169
2014 September	77	0	77
2014 August	79	0	79
2014 July	89	0	89
2014 June	113	0	113
2014 May	107	0	107
2014 April	133	0	133
2014 March	165	0	165
2014 February	131	0	131
2014 January	112	0	112
2013 December	78	0	78
2013 November	66	0	66
2013 October	71	0	71
2013 September	68	0	68
2013 August	82	0	82
2013 July	72	0	72
2013 June	47	0	47
2013 May	51	0	51
2013 April	24	0	24
2013 March	16	0	16
2000 January	1336	0	1336

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter